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Abstract 
Familial Hypercholesterolaemia (FH) is an autosomal dominant inherited condition 
characterised by increased blood cholesterol levels which leads to xanthomas and 
coronary heart disease. Prevalence of FH worldwide as well as in the UK is 1 in 250-500. 
Almost 85% of people with FH still remain undiagnosed. FH is predominantly caused by 
mutations in the three genes LDLR, APOB and PCSK9. 
  
Aim 
To set up Next Generation Sequencing (NGS) methodology for genetic screening of FH. 
 
Methods 
A retrospective cohort of 94 patients known and suspected to suffer from FH were 
selected for targeted sequencing on LDLR, APOB, PCSK9, LDLRAP1 and APOE genes 
using an Illumina MiSeq system. Data analysis was performed with BaseSpace and 
Galaxy platforms. Sanger sequencing was performed as a gap filling for NGS. 
 
Results 
A total of 94 samples were screened by the reference lab of which 58 patients had no 
reported FH variants. Our NGS approach allowed the identification of FH variants in 62 
patients out the 94 samples. Of these, 32 patients had variants identified in LDLR, 27 
patients in APOB, 14 patients had variants in APOE and 1 patient had a variant in the 
PCSK9 gene. Furthermore, 10 patients had variants identified in both LDLR and APOB 
genes, 4 patients in LDLR and APOE and 3 patients in APOB and APOE.  
 
Conclusion and impact 
This study has demonstrated the practical utility of NGS as a diagnostic platform for 
genetic disorders such as FH to be used by the NHS of the future. NGS represents a 
paradigm shift from the conventional Sanger sequencing in its ever-increasing breadth of 
coverage, resolution and reliability, coupled with ever-reducing costs. Therefore, 
incorporation of NGS into routine molecular diagnostics will create a major impact on the 
way we diagnose and tailor the management of hereditary disorders such as FH. 
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1.1  Familial hypercholesterolaemia 
Familial hypercholesterolemia (FH, OMIM no. 143890) is an autosomal dominant inherited 
disorder of lipoprotein metabolism characterised by raised blood plasma cholesterol levels 
(J L Goldstein & Brown, 1973) (Brown & Goldstein, 1974) and was first described in 1920 
(Burns, 1920). Increased plasma cholesterol levels result in its deposition in peripheral 
tissues leading to xanthomas (A. K. Soutar & Naoumova, 2007) (Fahed & Nemer, 2011) 
and deposition in arterial wall leads to coronary heart disease (CHD) (Goldstein JL, Hobbs 
HH, Brown MS, 2001) (Khachadurian, 1988). As a result of raised blood cholesterol 
levels, men are at almost 50% risk of fatal or non-fatal CHD by the age of 50 and is 
slightly lower in women, who are at risk of almost 30% by the age of 60 (Slack, 1969) 
(Stone, Levy, Fredrickson, & Verter, 1974). It was in 1938, a Norwegian physician, Carl 
Müller in his landmark paper showed the connection between plasma cholesterol and 
heart attacks (Müller, 1938). In his paper, he had described 17 Norwegian families with 76 
family members who had xanthomas, high cholesterol, myocardial infarction and 68 
members of the family had symptoms of possible heart disease (Müller, 1938). 
1.2  Disease prevalence 
FH exists in both homozygous and heterozygous forms. Heterozygous FH (HeFH) is more 
common and  the prevalence of HeFH worldwide as well as in the UK was known to be 
1:500 (Goldstein JL, Hobbs HH, Brown MS, 2001) (Scriver, 1995). However, recent 
population based studies in UK (Wald et al., 2016), the Netherlands (Barbara Sjouke et 
al., 2015), northern Europe (Benn, Watts, Tybjærg-Hansen, & Nordestgaard, 2016), 
Poland (Pajak et al., 2016) and the United States (Abul-Husn et al., 2016) reveal the 
prevalence to be 1 in 200-250, twice as high as previously thought. Furthermore, due to 
founder effects the prevalence is even higher in certain populations, such as 1 in 200 in 
French Canadians, 1 in 165 in Tunisians, 1 in 85 in Christian Lebanese, and in South 
African Afrikaners it is 1 in 72 (Austin, Hutter, Zimmern, & Humphries, 2004). Such 
founder effects are also found in Finns, Icelanders, Gujarati South African Indians and 
Ashkenazi Jews (Henderson, O’Kane, McGilligan, & Watterson, 2016). Homozygous FH 
(HoFH) is extremely rare with a frequency of 1 in 1,000,000 individuals (Bhagavan & 
Jackson, 2002) (Rader, Cohen, & Hobbs, 2003) and in certain populations it is known to 
be 1 in 160,000 to 1 in 300,000 (Barbara Sjouke et al., 2015) (Cuchel et al., 2014). Using 
these prevalence figures, it is estimated that almost 34 million individuals worldwide have 
FH and less than 1% have been diagnosed (Iacocca et al., 2017). In the UK, the 
proportion of patients with FH identified and being treated in the lipid clinics is 
approximately 15% which therefore indicates that almost 85% of people with FH still 
remain undiagnosed (D Marks, Thorogood, Farrer, & Humphries, 2004) (Neil, Hammond, 
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Huxley, Matthews, & Humphries, 2000) . The Netherlands, Norway and Japan are the 
only countries known to have high diagnostic rates of 86%, 37% and 26% as shown in 
Figure 1.  
Underdiagnosis of FH has been mainly due the failure in implementation of national 
guidelines such as NICE in the UK, poor availability of genetic services, low through put 
from traditional screening methodologies, high costs of traditional genetic testing, 
fragmented service delivery and also due to the lack of investment in identification of 
index cases (Norsworthy et al., 2014). Undertreatment has been due to the lack of 
awareness of the pathogenicity of FH, fear of side effects of statins, lack of knowledge 
about the efficacy and importance of statin treatment among patients and healthcare 
providers, lack of universal screening programmes for FH, lack of electronic health record 
systems and lack of national registries to monitor and follow-up FH patients (Haymana, 
2017) (Metha et al., 2016). 
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Figure 1 Diagnosis of familial hypercholesterolaemia (FH) worldwide in 2017 based on a frequency of 1:250 (Borge G Nordestgaard & Benn, 2017). 
LDL-C: Low density lipoprotein concentration. 
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1.3  Hepatic cholesterol homeostasis 
Cholesterol is an essential component of the cell membranes and also acts as a precursor 
to steroidal and non-steroidal hormones. Cholesterol is essential for normal cellular 
functions and each day the human body synthesises 700-900 mg of cholesterol and 
absorbs 300-500 mg of cholesterol from diet (Dietschy, 1984). In humans, cholesterol is 
mainly synthesised in the liver, intestine, adrenal glands and in the reproductive organs 
(Russell, 1992). Cholesterol is transported in the blood as five major lipoproteins, 
chylomicrons (CM), very low density lipoprotein (VLDL), intermediate density lipoprotein 
(IDL), low density lipoprotein (LDL) and the high density lipoprotein (HDL) (Wadhera, 
Steen, Khan, Giugliano, & Foody, 2016). In common parlance, LDL is often called the 
“bad” cholesterol due to its risk of causing atherosclerosis whilst “HDL” is known as the 
good cholesterol due to its protective effects. There are three distinct mechanisms in the 
liver through which cholesterol homeostasis occurs: endogenous cholesterol synthesis, 
LDLR expression on the liver cells, and cholesterol excretion as bile acids by reverse 
cholesterol transport (A David Marais, 2004). 
1.3.1 Endogenous pathway 
VLDL is synthesised along with the apolipoprotein ApoB-100 and is secreted by the liver 
(Nguyen et al., 2008). In circulation, VLDL acquires ApoC and ApoE from the circulating 
HDL particles. VLDL is hydrolysed by lipoprotein lipase leading to the formation of fatty 
acids and glycerol. During this process VLDL loses ApoC to the HDL resulting into the 
transformation of IDL. IDL is either taken up by the LDLR or converted to LDL by the 
action of hepatic lipase (shown in Figure 2) and during this process IDL molecule loses 
ApoE to the HDL molecules. LDL particles with ApoB enter the liver through the LDLR 
pathway which further gets metabolised to bile acids (T. F. Daniels, Killinger, Michal, 
Wright, & Jiang, 2009) and excreted in the faeces. 
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Figure 2 Endogenous pathway of cholesterol homeostasis. VLDL: Very low density lipoprotein, B100: APOB100, APOC: Apolipoprotein C, APOE: 
Apolipoprotein E, APOA: Apolipoprotein A, LPL: Lipoprotein lipase, HL: Heaptic lipase, LDLR: Low density lipoprotein receptor. 
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1.3.2 LDLR pathway 
The LDL receptor pathway characterised by Brown and Goldstein for the uptake and 
degradation of LDL is shown in Figure 3. LDL receptor is a cell surface glycoprotein 
synthesised by the endoplasmic reticulum (ER) and processed by the Golgi apparatus (A. 
K. Soutar & Naoumova, 2007). The mature form of the LDL receptor anchors to the 
hepatic cell membrane. The circulating LDL particles bind to the LDL receptor specifically 
through the APOB component of the LDL particle (A. K. Soutar & Naoumova, 2007). The 
receptor-ligand complex is then internalised by the process of endocytosis through the 
clathrin-coated pits and forms a vesicle through its interaction with the LDL receptor 
adaptor protein (J L Goldstein, Anderson, & Brown, 1982). The vesicle is transported to 
the endosomes and the acidic environment in the endosomes causes the dissociation of 
the LDL particles from the LDL receptors (A. K. Soutar & Naoumova, 2007) (Brautbar et 
al., 2015). LDL receptors are either degraded or recycled back to the cell surface 
(Brautbar et al., 2015). LDL particles are degraded in the lysosomes where the APOB is 
converted to amino acids and cholesterol esters are converted to free cholesterol which is 
used in the synthesis of cell membranes, steroid hormones and bile acids (J L Goldstein 
et al., 1982). Proprotein convertase subtilisin/kexin-9 synthesised by the Golgi is involved 
in the degradation of the LDL receptors and prevents it from being recycled back to the 
cell surface (Brautbar et al., 2015). 
 
 
 
 
 
 
 
 
 
 
 
 
8 
 
 
Figure 3 LDLR receptor pathway for the uptake and degradation of LDL. LDL: Low density lipoprotein, APOB: Apolipoprotein B, LDLR: Low density 
lipoprotein rceptor, PCSK9: Proprotein convertase subtilisin/kexin-9. 
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1.3.3 Reverse cholesterol transport 
In this pathway, HDL particles transport cholesterol from the arterial walls and peripheral 
tissues back to the liver where it can be catabolised and excreted as bile (Moffatt & 
Stamford, 2005). Hence, HDL is also termed as good cholesterol since it controls the bad 
cholesterol (LDL) levels and protects from CHD (Gordon et al., 1989). This pathway relies 
on the availability of a group of apolipoproteins, enzymes, transfer proteins and receptors 
(Moffatt & Stamford, 2005). Amongst these, HDL contains ApoA, functions as an acceptor 
of cholesterol as well as serves a co-factor for lecithin cholesterol acyl transferase (LCAT) 
(D. P. Nicholls, Nicholls, & Young, 2009). 
1.4 Pathophysiology of FH 
Mutations in any of the FH causing genes leads to raised blood plasma cholesterol levels. 
In children, the cholesterol level is usually >6.7 mmol/l and in adults it is >7.5 mmol/l 
(“Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering 
Committee on behalf of the Simon Broome Register Group,” 1991). Raised blood plasma 
cholesterol levels results in its deposition in peripheral tissues leading to xanthomas and 
deposition in the blood vessels leading to the formation of atherosclerotic plaques and 
consequently, CHD. 
1.4.1 Xanthomas 
Deposition of cholesterol in tendons leads to thickening of the tendons and causes tendon 
xanthomata as shown in panel B, C and D of Figure 4. It is composed of monocyte-
derived foam cells which can accumulate and store cholesterol intracellularly (Kruth, 
1985). Tendon xanthomata usually occur in the elbows, Achilles tendon and hands. 
Deposition of cholesterol in the cornea of the eye leads to corneal arcus which usually 
appears as a crescent white line. Deposition of cholesterol in the eyelids leads to 
xanthelasma which appears as a flat yellow plaque on the eye lids. 
 
Figure 4 Deposition of cholesterol in peripheral tissues. A= Corneal arcus and xanthelasma, 
B= Extensor tendon xanthomas, C and D= Achilles tendon xanthomas. Reproduced with 
permission from Burnett et al (D. A. Bell, Hooper, Watts, & Burnett, 2012). 
 
A B C D 
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1.4.2 Atherosclerosis 
Raised blood plasma LDL cholesterol for prolonged period leads to its deposition into the 
arterial blood vessel walls, leading to atherosclerosis as shown in Figure 5. LDL in 
circulation is oxidised and initiates an inflammatory response damaging the endothelial 
tissues to form atherosclerotic plaques (Van Wijk et al., 2014). Oxidised LDL enters the 
endothelial cell surface where it is phagocytosed by monocytes (Stocker, 2004). 
Monocytes acquire the characteristics of macrophages and undergo a series of changes 
to develop into a foam cell (Libby, 2002). Cholesterol intake by macrophages is facilitated 
by the scavenger receptors and is capable of accumulating vast stores of cholesterol 
esters (A D Marais & Firth, 2005). Scavenger receptors are a diverse group of receptors 
which are involved in the uptake of oxidised lipoproteins and are expressed by the 
macrophages in the atherosclerotic plaques and by circulating monocytes in atherogenic 
conditions (Kzhyshkowska, Neyen, & Gordon, 2012).  
The early atherosclerotic lesion is characterised by these lipid-laden macrophages called 
foam cells which leads to the formation of a so-called fatty streak (Libby, 2002). A fatty 
streak develops into an atheroma along with the proliferation of smooth muscle cells 
which evolves into a plaque and occludes the blood vessel by narrowing the lumen of the 
arteries. Stenotic lesions, produced by the atherosclerotic plaques, restrict the blood flow, 
leading to ischaemia (Libby, 2002). Disruption and rupture of these atherosclerotic 
plaques allows contact with tissue factor in the blood, which triggers thrombus formation 
(Davies, 1996). Thrombus formation contributes to occlusion of blood vessel, which is a 
precursor to acute myocardial infarction (MI) (Libby, 2002).  
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Figure 5 Atherosclerosis formation in the blood vessel of patients with raised LDL. Oxidised LDL initiates an inflammatory response on the endothelial 
cells. Oxidised LDL cholesterol is engulfed by the macrophages and develops into foam cells loaded with LDL particles. Accumulation of foam cells leads to 
the atherosclerotic plaque formation. Rupture of the plaque leads to thrombus formation. 
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1.5  FH genes 
The hereditary basis of the FH was first demonstrated by Wilkinson et al (Wilkinson, 
Hand, & Fliegelman, 1948) and later on Khachadurian demonstrated the autosomal-
dominant mode of inheritance (Khachadurian, 1964). FH is predominantly caused by 
mutations in the genes coding for three proteins: Low Density Lipoprotein Receptor 
(LDLR) (Hobbs, Brown, & Goldstein, 1992a) (Scriver, 1995), Apolipoprotein B (APOB) 
(Soria et al., 1989), and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) (M 
Abifadel et al., 2003). A very rare recessive form of FH is caused by mutations in the Low 
Density Lipoprotein Receptor Adaptor Protein (LDLRAP1) (Henderson et al., 2016) (A. K. 
Soutar & Naoumova, 2007) (Faiz, Hooper, & Van Bockxmeer, 2012). However, recently 
Apolipoprotein E (APOE) is known to cause FH in certain families (Cenarro et al., 2016) 
(Awan et al., 2013). To date, according to the Leiden Open Variation Database (LOVD) an 
web-based platform designed by the Netherlands, to collect and display variants in the 
DNA sequence has 1741 variants reported in the LDLR gene (S. E. Leigh, Foster, 
Whittall, Hubbart, & Humphries, 2008), 69 variants in APOB gene of which only 8 variants 
are known to cause FH (Henderson et al., 2016), and 163 variants in the PCSK9 gene (S. 
E. A. Leigh, Leren, & Humphries, 2009). It has been reported that almost 79% of FH 
patients carry a mutation in their LDLR gene, 5.5% carry a mutation in their APOB gene 
and 1.5% carry a mutation in their PCSK9 gene (Tosi, Toledo-Leiva, Neuwirth, 
Naoumova, & Soutar, 2007) (Henderson et al., 2016) (De Castro-Orós, Pocoví, & Civeira, 
2010). The remaining 15% of the FH cases are either polygenic or the genetic cause is 
still unknown (Wiegman et al., 2015). 
It is also evident from the literature that there could be other genes involved in FH, for 
which evidence is still evolving and emerging (Vandrovcova et al., 2013). The patient may 
have FH caused by a very rare mutation in a gene which is yet to be discovered and 
hence researchers have started screening other genes in the cholesterol-processing 
pathways (Vandrovcova et al., 2013) (Thomas, 2015). In addition, there could also be 
variants which have been identified, but lack sufficient evidence for being the cause of FH 
(Thomas, 2015). 
Mutations in the APOB and the LDLR gene results in defective binding of LDL particles to 
the LDL receptors on the cell surface (Brautbar et al., 2015). As a result, LDL cannot be 
internalised by the hepatic cell for degradation, which results in raised blood plasma LDL 
cholesterol levels. A mutation in the LDLRAP1 gene prevents the internalisation of the 
receptor-ligand complex into the hepatic cell (Brautbar et al., 2015). A gain-of-function 
mutation in the PCSK9 gene leads to increased degradation of the LDL receptor and 
prevents it from being recycled (Brautbar et al., 2015). 
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1.5.1 LDLR 
LDLR was first discovered in 1974 by Goldstein and Brown (J. L. Goldstein & Brown, 
1974). In 1986 they discovered the LDLR molecular defect underlying FH (M S Brown & 
Goldstein, 1986) and were later awarded the Nobel Prize for this work. LDLR is a cell 
surface glycoprotein receptor expressed on the surface of hepatocytes and regulates the 
LDL concentration in the blood by removing them from circulation and aids in hepatic 
cholesterol homeostasis. The 45 kilobase (kb) LDLR gene (MIM 606945) is located on the 
short arm of chromosome 19 (19p13.2) and consists of 18 exons and 17 introns 
(Henderson et al., 2016) as shown in Figure 6. The LDLR protein is comprised of five 
structural domains encoded by exons 2 to 18 (A. Soutar, 2009). Exon 1 encodes a signal 
peptide which is required for the transport of the LDLR to the ER. Exon 2 to 6 encodes the 
functional domain which is responsible for binding of lipoprotein particles. Epidermal 
Growth Factor (EGF) precursor-like domain is encoded by exons 7 to 14 which play a 
significant role in dissociation of LDLR-LDL complex in the endosomes. Oligosaccharide 
rich domain is encoded by exon 15 and deletion of this domain does not appear to have 
any effect on the LDLR function in vitro (Davis et al., 1986). Transmembrane (TM) domain 
rich in hydrophobic amino acids is encoded by exon 16 and aids in anchoring LDLR to the 
cell membrane. The cytoplasmic domain is encoded by exons 17 and 18 and is 
responsible for ensuring the correct orientation of LDLR as well as directing the LDLR-
LDL complex to the clathrin coated pit during endocytosis (Hussain, Strickland, & Bakillah, 
1999). To date, 1741 mutations (S. E. Leigh et al., 2008) have been identified in the exons 
of the LDLR gene and these have been divided into five categories based on their effects 
on the LDLR. Class 1 mutations are defined as null mutations since they result in no 
detectable LDLR protein (Hopkins, Toth, Ballantyne, & Rader, 2011) (Hobbs, Russell, 
Brown, & Goldstein, 1990). In class 2, there are two subclasses: 2a and 2b, where the 
transport of LDLR from the ER to Golgi is blocked completely (2a) or partially blocked (2b) 
(Hobbs, Brown, & Goldstein, 1992b) (Hopkins et al., 2011) (Hobbs et al., 1990). Class 3 
mutations lead to the production of defective or non-functional LDLR (Hopkins et al., 
2011) (Hobbs et al., 1990). Class 4 mutations are due to defective internalisation of the 
LDLR and LDL complex via clathrin-coated pits (Hopkins et al., 2011) (Hobbs et al., 
1990). Class 5 mutations arise due to defects in the recycling of LDLR (Hopkins et al., 
2011) (Hobbs et al., 1990). More than 90% of the reported variants are disease causing 
variants (Usifo et al., 2012) and the majority of these are clustered around exon 4 
(Grenkowitz et al., 2016). 
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Figure 6 LDLR gene located on the short (p) arm of chromosome 19 at position 13.2 (19p13.2). Numbered vertical bars represent the exons which 
encode the various domains of the LDLR protein. OLS: O-linked sugar domain, TM: Transmembrane domain. Mutations can affect any domain of the LDLR 
protein and can result in defective or impaired binding of LDL particle to the LDLR and also can results in impaired internalisation of the complex into the cell.
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1.5.2 APOB 
The 42-kb APOB gene (MIM 107730) is located on the short arm of chromosome 2 
between 2p23-p24 and consists of 29 exons and 28 introns (Huang, Miller, Bruns, & 
Breslow, 1986) (Law et al., 1985). The APOB gene gives rise to two isoforms of APOB 
protein; apoB-100, found in the LDL particles and is expressed in the liver cells and apoB-
48 expressed in the small intestine (Whitfield, Barrett, Van Bockxmeer, & Burnett, 2004). 
APOB-100 is 4,563 amino acids in length and contains five domains: NH3-ßα1-ß-α2-ß2-
α3-COOH (S. H. Chen et al., 1986) (Segrest, Jones, De Loof, & Dashti, 2001) as shown in 
Figure 7. Mutations in the APOB gene lead to familial defective APOB-100 (FDB) 
(Innerarity et al., 1990). The binding region for the microsomal triglyceride transfer protein 
(MTTP) which is very significant for the lipoprotein assembly is present on the ßα1 domain 
(White, Bennett, Billett, & Salter, 1998). ß1 and ß2 domains can irreversibly bind to the 
lipids, while α2 and α3 can bind reversibly (Segrest et al., 2001). In addition ß2 domain 
also contains the LDLR binding region which is essential for the uptake of lipoproteins 
containing APOB-100 (Whitfield et al., 2004). FDB results in production of defective 
APOB-100 protein, which results in defective binding of APOB to LDLR and thereby fails 
to clear LDL from the circulation (Innerarity et al., 1990). In contrast to LDLR, there are 
only 8 disease causing variants and the majority of these variants are located on exon 26 
(Henderson et al., 2016). The most common APOB gene variant Arg3527Gln, which is 
due to R3500Q at the gene level, is known to disrupt the conformational binding of LDL to 
its receptor (Borén, Ekström, Ågren, Nilsson-Ehle, & Innerarity, 2001). The prevalence of 
this mutation is known to be 1 in 500 to 1 in 1000 and varies with the population being 
studied (Innerarity et al., 1990). A Danish study has also shown the prevalence of this 
mutation in the general population to be 1 in 1000 and was associated with a significant 
increase in blood plasma cholesterol levels (Tybjærg-Hansen, Steffensen, Meinertz, 
Schnohr, & Nordestgaard, 1998). 
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Figure 7 APOB gene located on the short (p) arm of chromosome 2. Numbered vertical bars represent the exons. To-date there are 8 known disease 
causing variants and the majority of them are located in exon 26.
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1.5.3 PCSK9 
PCSK9 (MIM 607786) codes for a 25 kb serine protease (Marianne Abifadel et al., 2014), 
which belongs to the proprotein convertase family (Seidah & Prat, 2007) and is mainly 
expressed in the liver, intestine and the kidneys (Seidah et al., 2003) (Kwon, Lagace, 
McNutt, Horton, & Deisenhofer, 2008) (Zhang et al., 2007). Human PCSK9 is located on 
the short (p) arm of chromosome 1 at position 32.3 and contains 12 exons and 11 introns 
(Seidah et al., 2003) (Hunt et al., 2000). The protein consists of 692 amino acids 
(Marianne Abifadel et al., 2014) and contains N-terminal pro-domain, catalytic domain, 
and a cysteine- and histidine-rich C- terminal domain as shown in Figure 8 (Cariou, Le 
May, & Costet, 2011) (Pandit et al., 2008). PCSK9 regulates cholesterol levels in the body 
through its interaction with the EGF domain of the LDLR (Zhang et al., 2007). Mutations in 
the PCSK9 gene are rare and it was first found in French families (M Abifadel et al., 
2003). However, it is now known to be associated with severe hypercholesterolaemia in a 
number of families in several countries (Leren, 2004) (Sun et al., 2005) (Timms et al., 
2004). Gain of function mutations in the PCSK9 gene causes hypercholesterolaemia and 
the exact underlying mechanism in not fully understood (Faiz et al., 2012). However, it is 
known that PCSK9 gene encodes an enzyme which is involved in the regulation and 
degradation of the LDLR receptor protein and preventing it from being recycled. Hence, in 
the recent times the inhibition of PCSK9 has been of great interest to the pharmaceutical 
industry as an important target for development of new drugs to FH (A. K. Soutar & 
Naoumova, 2007).  PCSK9 gene mutations account for 1.5% clinically diagnosed FH (De 
Castro-Orós et al., 2010) and are commonly seen as heterozygotes, homozygotes and 
compound heterozygous on their own or in combination with LDLR mutations as double 
heterozygotes (Brautbar et al., 2015). 
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Figure 8 PCSK9 gene located on the short (p) arm of chromosome 1 at position 32.3 (1p32.3). Numbered vertical bars represent the exons which 
encode the various domains of the PCSK9 protein. To date 163 mutations are known in the PCSK9 gene, some of which cause gain-of-function whilst some 
cause loss-of-function. 
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1.5.4 LDLRAP1 
The 25-kb LDLRAP1 gene is located on the short (p) arm of chromosome 1 at position 
36.11 which contains 9 exons and 8 introns. It yields a protein product containing 308 
amino acids with 3 functional domains: phosphotyrosine-binding domain (PTB), a type- 1 
clathrin box (LLDLE) and an adaptor protein 2 (AP2)-binding domain (Figure 9). Loss-of-
function mutations in the LDLRAP1 gene causes Autosomal Recessive 
Hypercholesterolaemia (ARH) and was first noted by Khachadurian (Khachadurian, 1964). 
One of the main functions of LDLRAP1 is to facilitate the endocytosis of LDLR in the 
clathrin-coated pits of the hepatocytes. However, in ARH due mutations in the LDLRAP1, 
the LDL-C ligand and receptor complex cannot be internalised in the hepatocytes which 
results in impaired catabolism of LDL-C. ARH are extremely rare with an estimated 
frequency of 1 in 5,000,000 (Rader et al., 2003). The prevalence of ARH is high in 
Sardinia, Italy; at around 1 in 40,000, presumably due to founder effects, consanguineous 
marriages and due to its isolated geographical location (Filigheddu et al., 2009). To date, 
there are 39 mutations reported in the LDLRAP1 gene (Henderson et al., 2016). The 
phenotype for both ARH and homozygous FH due to LDLR are similar (Pisciotta et al., 
2006). However, total serum cholesterol and LDL cholesterol levels are lower and when 
compared to homozygous FH caused by LDLR (A. K. Soutar & Naoumova, 2007). In 
addition, ARH patients tend to have high HDL cholesterol in comparison to patients with 
homozygous FH due to LDLR mutations (Pisciotta et al., 2006). 
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Figure 9 LDLRAP1 gene located on the short (p) arm of chromosome 1 at position 36.11 (1p36.11). Numbered vertical bars represent the exons which 
encodes to the respective domains of the LDLRAP1 protein. PTB domain: phosphotyrosine–binding domain, AP-2: adaptor protein 2. 
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1.5.5 APOE 
APOE gene is located on the long (q) arm of chromosome 19 at position 13.32 
(19q13.32). The APOE gene consists of 4 exons and 3 introns and encodes a protein 
called apolipoprotein E (ApoE) with 299 amino acids with a molecular mass of ~34kDa 
(Zhao, Liu, Qiao, & Bu, 2018). The receptor binding domain of the ApoE is in the N-
terminal domain and the lipid binding domain is in the C-terminal domain as shown in the 
Figure 10. The gene produces a multifunctional glycosylated protein synthesised in 
several organs such as liver, brain, kidney and spleen (Awan et al., 2013) (Mahley, 1988). 
ApoE is a key component of chylomicrons, chylomicron remnants and very low density 
lipoprotein (VLDL) (Awan et al., 2013). It acts as a ligand for LDLR and transports 
cholesterol and other lipids among various cells of the body (Mahley, 1988). A mutation in 
the APOE gene leads to defective binding of LDLR which is characterised by raised blood 
cholesterol levels and accelerated coronary artery disease (Mahley, 1988). Through 
genome wide association studies (GWAS), it is evident that the APOE gene is strongly 
associated with LDL-C levels (Asselbergs et al., 2012). Recent evidences from the 
literature indicate that APOE could be another gene candidate causing FH (Solanas-
Barca et al., 2012) (Marduel et al., 2013). In particular APOE p.Leu167del mutation has 
been predicted to alter the ApoE protein structure and weaken its lipoprotein binding link 
with the LDLR (Awan et al., 2013). 
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Figure 10 APOE gene located on the long (q) arm of chromosome 19 at position 13.32 (19q13.32). Numbered vertical bars represent exons. 
Apolipoprotein E forms the major component of chylomicrons. 
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1.6 Diagnosis 
FH is a public health problem and studies have shown that FH is underdiagnosed and 
undertreated throughout the world (Børge G. Nordestgaard et al., 2013). The Netherlands, 
Norway and Japan are the only countries known to have high diagnostic rates of 86%, 
37% and 26% respectively, whereas the diagnostic rates in the rest of the world is known 
to be less than 10% (Borge G Nordestgaard & Benn, 2017). In the UK, only 12% of the 
population are known to be diagnosed (Børge G. Nordestgaard et al., 2013) and an audit 
by the Royal College of Physicians has therefore indicated that 85% of the individuals with 
FH remain undiagnosed (Mooney, 2011). Generally, diagnosis is primarily based on family 
history, clinical history of CHD, physical examination for xanthomas, repeated 
measurements of high blood plasma cholesterol levels and by genetic diagnosis (F 
Civeira, 2004). Despite being cost-effective, this approach risks missing 30-60% of the 
affected patients (S. R. Daniels & Greer, 2008). Moreover, diagnosis solely based on 
physical examination and family histories are not effective as family studies are 
complicated and some of the features of FH occur only in the adulthood (Heath, 
Humphries, Middleton-Price, & Boxer, 2001). In addition, studies have also shown that low 
cholesterol levels were observed in individuals with certain LDLR mutation carriers and 
hence measurement of cholesterol levels alone are not effective in diagnosis (Hobbs et 
al., 1989) (Koivisto, Koivisto, Miettinen, & Kontula, 1992) (Sass et al., 2004). Hence, 
currently, FH is diagnosed based on biochemical, clinical and genetic diagnosis (Watts et 
al., 2011) (D Marks, Thorogood, Neil, & Humphries, 2003).   
1.6.1 Biochemical diagnosis 
FH is primarily diagnosed by biochemical diagnosis whereby patient’s blood plasma 
cholesterol levels are measured and at least two elevated blood plasma cholesterol 
measurements are required. Serial measurements of blood cholesterol levels, in particular 
LDL cholesterol, aid in the diagnosis of FH. However, cholesterol levels vary with age, sex 
and the population group and hence it is important to establish a cut-off based on the 
above parameters (D Marks et al., 2003). In the UK, based on the Simon-Broome 
Diagnostic Criteria, the cut-off for total cholesterol and LDL cholesterol for children is set 
to >6.7 mmol/l and >4.0 mmol/l and for adults it is >7.5 mmol/l and >4.9 mmol/l (“Risk of 
fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering 
Committee on behalf of the Simon Broome Register Group,” 1991). LDL cholesterol is 
known to be the driving factor for CHD and hence fasting lipid profile is requested by the 
GPs and clinicians in the lipid clinic as the first line of the obligatory biochemical screening 
process where LDL cholesterol is calculated using the Friedewald formula (Friedewald, 
Levy, & Fredrickson, 1972). However, studies have shown that almost 15-20% patients 
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would have been misdiagnosed based on cholesterol testing alone (Koivisto et al., 1992) 
(Ward et al., 1996). Hence, biochemical coupled with clinical and genetic diagnosis would 
be expected to be the most effective way to diagnose and screen patients suspected to 
have FH. 
1.6.2 Clinical diagnosis 
Several diagnostic criteria have been developed to clinically diagnose FH throughout the 
world and no international standard currently exists (Fahed & Nemer, 2011). There are 
currently three widely used clinical diagnostic criteria which supplement the use of blood 
plasma cholesterol levels, clinical signs, family history and genetic diagnosis. The three 
widely used clinical diagnostic tools are Simon Broome criteria (“Risk of fatal coronary 
heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf 
of the Simon Broome Register Group,” 1991), Dutch Lipid Clinic Network (DLCN) (WHO, 
1999) and Make Early Diagnosis to Prevent Early Deaths (MEDPED) criteria (Williams et 
al., 1993). In the UK, the Simon Broome criteria are followed, which classifies the patient 
as definite FH or possible FH based on the blood cholesterol and LDL cholesterol levels, 
family history of myocardial infarction, presence of tendon xanthomata along with genetic 
diagnosis, as shown in Table 1. 
Table 1 Simon Broome criteria. 
Definite FH Possible FH 
Cholesterol:  >6.7 mmol/l (LDL > 4.0 mmol/l) in children under 16, 
    >7.5 mmol/l (LDL > 4.9 mmol/l) in adults. 
Plus either 
Tendon xanthomata in patient, 1st or 2nd 
degree relative. 
Plus either 
Family history of myocardial infarction 
<50yrs in 2nd degree relative or <60yrs in 1st 
degree relative. 
OR 
DNA confirmation. 
OR 
Family history of cholesterol >7.5mmol/l in 
1st or 2nd degree relative. 
FH: Familial hypercholesterolaemia, LDL: Low density lipoprotein. 
 
The DLCN tool is similar to the Simon Broome tool, but adds the calculation of a numeric 
score and is in use in some part of Europe. Based on the scores, diagnosis is considered 
to be certain if it is greater than 8 and probable if it is between 6 and 8 and is considered 
to be possible if the score is between 3 and 5. Any score below 3 is considered to be 
negative (F Civeira, 2004). The US MEDPED criteria take into account of age-specific and 
first degree and second degree relative specific criteria for total cholesterol only and do 
not take clinical characteristics, such as tendon xanthomata and an identification of a 
mutation into account (Williams et al., 1993). These clinical criteria are not expensive and 
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hence they are still being used for clinically diagnosing FH as well as to identify family 
members who may have FH. However, this process is not accurate in diagnosing index 
cases in the general population. 
1.6.3 Genetic diagnosis 
The definitive way of diagnosing FH, is by genetic testing whereby pathological mutations 
can be detected by a DNA based mutation screening (D Marks et al., 2003) (P. Nicholls, 
Young, Lyttle, & Graham, 2001). The National Institute for Health and Care Excellence 
(NICE) guidelines in the UK states, that genetic analysis is clinically more effective as well 
as cost-effective for the diagnosis of FH than LDL cholesterol screening (A S Wierzbicki, 
Humphries, & Minhas, 2008). It also states that all patients meeting the Simon Broome 
criteria should be offered a DNA test to confirm FH. So far, a combination of different 
genetic techniques have been used to genetically diagnose FH which has resulted in only 
few people being able to avail a genetic test partially due to cost implications as well as 
time associated with these screening methods (Maglio et al., 2014) (Thomas, 2015). 
Currently, Sanger sequencing is still considered as the gold standard for SNV mutation 
analysis and Multiplex ligation-dependent probe amplification (MLPA) is used for the 
detection of large insertions and deletions. Several of these traditional molecular 
screening methods are currently in use which varies in sensitivity (Maglio et al., 2014) 
(Sharma et al., 2012). However, recently genetic diagnosis through next generation 
sequencing (NGS) technology has created a major impact in the scientific and diagnostic 
community by allowing labs to run several samples in a single run as well as to analyse 
multiple genes. Genetic diagnosis through NGS has the potential to improve early disease 
identification, atherosclerosis risk prediction and aid in timely management. 
1.6.4 Cascade screening 
Cascade screening is a process of identifying people who are at risk of a genetic condition 
by systematically screening the families of the index case (Sturm, 2014). In cascade 
screening, an index patient is initially identified through confirmation of a mutation by 
genetic testing. On confirmation, the first degree relatives of the index patient are 
screened for the same mutation. New confirmed cases from the first degree are then 
treated as index cases and their first degree relatives are screened (Fahed & Nemer, 
2011). FH being a dominantly inherited condition makes cascade screening as an 
effective tool as half of the screened relatives of the index case will demonstrate the 
mutation (Faiz, Nguyen, Van Bockxmeer, & Hooper, 2014). In 1994, the Netherlands 
came up with the first successful model of cascade screening and to date this programme 
has identified 33,000 FH cases (Huijgen, Hutten, Kindt, Vissers, & Kastelein, 2012). In the 
UK, cascade screening has shown to be more cost-effective than universal screening 
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(Dalya Marks et al., 2002) and has been established in Scotland, Wales and Northern 
Ireland. It is also evident from the literature that genetic cascade screening programmes 
has been well received by the patients and their relatives (Faiz et al., 2014) as it releases 
the unaffected relatives from anxiety and further surveillance (Thomas, 2015). 
1.7  New approaches in molecular diagnosis 
We have witnessed the evolution of NGS technology and the way it has fuelled the 
diagnostics in a very short period of time. This state-of-art technology will increase our 
understanding of pathologies at molecular and cellular levels and aid in personalised 
medicine. These advancements will pave way for bringing healthcare research from the 
traditional “bench to bedside” and will also aid in genetic tests being the forefront of 
diagnostics and treatment. Currently, there are different NGS platforms available which 
share a common technological feature - massively parallel sequencing of clonally 
amplified or single DNA molecules that are spatially separated in a flow cell. These NGS 
platforms differ in sequencing chemistries and are capable of generating sequences of 
read length ranging from 35bp to 400bp. They require minimal DNA input as a starting 
material for construction of a library and output data ranges from few Mb to 600Gb per 
run. The run time also varies and ranges from 8 hours to 11.5 days based on the 
platforms.  
NGS for FH can be either performed as whole genome sequencing (WGS), whole exome 
sequencing (WES) or by using targeted gene panels. Each of these approaches has its 
advantages and disadvantages. WGS is universal, is capable of analysing non-coding 
regions and has more reliable coverage in comparison to WES (Majewski, 
Schwartzentruber, Lalonde, Montpetit, & Jabado, 2011). However, WES is more cost-
effective than WGS and has increased depth of sequencing (Majewski et al., 2011). In 
contrast, targeted gene panels are preferred for single gene disorders, such as FH, since 
they are less labour intensive and cost-effective in comparison to WGS and WES (Wu, 
Sun, Pan, Yang, & Wang, 2014). In addition, targeted gene panels do not pose any ethical 
issues due to incidental findings as in WGS and WES (Maglio et al., 2014). 
1.8  FH Management 
Early diagnosis and management of FH can significantly reduce the mortality and 
morbidity rates (Finnie et al., 2012). In the UK, National Institute for Health and Care 
Excellence (NICE) recommends that patients with FH should achieve a reduction in their 
LDL-cholesterol levels of more than 50% from their baseline (National Institute for Health 
and Clinical Excellence, 2017). The European Society of Cardiology/European 
Atherosclerosis Society (EAS) recommends the acceptable target levels of LDL-
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cholesterol in heterozygous patients with confirmed CHD as <1.8mmol/l and <2.5mmol/l in 
heterozygous patients without confirmed CHD (Børge G. Nordestgaard et al., 2013). 
Currently, statins are the first line of drugs in the treatment of patients with FH and there is 
large amount of evidence available to show that regular use of statins in FH patients can 
reduce the cardiovascular events (Catapano et al., 2011) (Baigent et al., 2010). Statins 
act by inhibiting HMG-CoA reductase, the rate-limiting step in cholesterol synthesis and by 
increasing the expression of LDL receptors resulting in lower plasma LDL cholesterol 
(Ooi, Barrett, & Watts, 2013). Large clinical trials (n=26) have shown overwhelming 
evidence that rigorous management with statins can significantly reduce cardiovascular 
mortality and morbidity (Baigent et al., 2010). In the UK, NICE guideline (CG71) 
recommends the use of statins in children from the age of 10 (Steve E Humphries, 
Cooper, Dale, & Ramaswami, 2018). However, it is evident from the literature that some 
patients not able to tolerate statins are not able to achieve the EAS recommended levels 
of LDL cholesterol (Pijlman et al., 2010). In such patients Ezetimibe could be the drug of 
choice which works by blocking the cholesterol absorption in the small intestine and is 
preferable to be given in combination with statins (Anthony S. Wierzbicki, Humphries, & 
Minhas, 2008). Alternative lipid lowering strategies with lifestyle modifications and drugs 
such as bile acid sequestrants, mipomersen, fibrates (Jun et al., 2010), niacin (Ganji, 
Kamanna, & Kashyap, 2003) and PCSK9 inhibitors (Reiner, 2015) in combination with 
statins should be considered (B Sjouke, Kusters, Kastelein, & Hovingh, 2011). In 
homozygote FH patients with extremely high blood plasma cholesterol levels, lipoprotein 
apheresis (Varghese, 2014) should be considered and gene replacement therapy should 
be explored for reducing the LDL cholesterol levels (Raper, Kolansky, & Cuchel, 2012). 
1.9  Gaps in the literature and problems with the current diagnostic 
methods 
It is evident from the literature that there is currently no single genetic test that is effective 
for screening and diagnosing FH patients. There are several studies that have reported 
the use of a combination of DNA tests for FH screening and diagnosis (Chiou, Charng, & 
Chang, 2011) (Duskova et al., 2011) (Finnie et al., 2012) (C A Graham et al., 2005) 
(Heath et al., 2001) (Palacios et al., 2012). However, these studies have shown a wide 
variation in sensitivity (34%-100%) and specificity (28%-99.1%) and have concluded that 
the poor sensitivity and specificity observed could be due to the screening methods 
employed as well as patient selection. Another key finding which could have played a 
significant role in altering the sensitivity and specificity rate in these studies is using 
different clinical diagnostic criteria in selecting patients. Some studies (Chiou et al., 2011) 
(Finnie et al., 2012) (Futema, Plagnol, Whittall, Neil, & Humphries, 2012) (C A Graham et 
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al., 2005) (Heath et al., 2001) (Vandrovcova et al., 2013) have employed Simon Broome 
criteria while a few others (Duskova et al., 2011) (Palacios et al., 2012) have used DLCN 
and MEDPED criteria. This also highlights the fact that there are currently no universal 
guidelines that could be accepted and used in the clinical diagnosis of these FH patients. 
Two recent targeted NGS based studies in the UK have shown a very high sensitivity and 
specificity rate highlighting the significance and potential of NGS based approaches in the 
screening and diagnosis of FH (Vandrovcova et al., 2013) (Futema et al., 2012). 
Furthermore, a Latvian study has shown that NGS based approach can be used to detect 
FH in high-risk individuals who do not meet the defined clinical criteria (Radovica-Spalvina 
et al., 2015). In addition, a recent Canadian study has shown that NGS based approach 
can also be used in detecting LDLR gene copy number variants in patients with FH and 
has also concluded that MLPA can be removed from routine diagnostic screening 
(Iacocca et al., 2017). Furthermore, as evident from the literature it could be argued that 
microarray studies (Chiou et al., 2011) (Duskova et al., 2011) have also shown a very high 
reproducibility rate of 99.99% and a mutation-pick up rate of 98.9% similar to the NGS 
studies; therefore, this platform could also be a powerful new tool for genetic screening 
and diagnosis of FH patients. However, perhaps a major limitation of micro-array methods 
is that they are not capable of picking up novel mutations. Furthermore, the microarray 
chips also require regular updates with new insertions and deletions into their tiling 
(Palacios et al., 2012). Moreover, microarrays are specifically designed and are only 
capable of picking up mutations most common to a specific population and therefore may 
not be applicable for a wider global population. Therefore, its application may not be 
optimal to a multi-cultural society such as UK. 
Many clinically diagnosed FH patients with raised blood plasma cholesterol levels fail to 
show mutations in the known FH causing genes (Fahed & Nemer, 2011). This suggests 
that there could be mutations in other novel genes involved in the cholesterol metabolic 
pathway which are yet to be discovered (Fahed & Nemer, 2011). In addition, current 
traditional screening methodologies also vary in sensitivity which could also lead to 
diagnostic gaps. Researchers in Canada have studied this diagnostic gap and have 
shown that exon-by-exon sequencing is capable of diagnosing only two thirds of FH 
patients (J. Wang, Ban, & Hegele, 2005). They have reduced the diagnostic gap from 
30% to 10% by detecting copy number variants through Multiplex Ligation Dependent 
Probe Amplification (MLPA) (J. Wang et al., 2005). However, there could be a number of 
reasons for having a negative result through genetic testing-a mutation could have been 
missed due to technical reasons, a variant could have been detected but there is not 
enough evidence to prove that it is pathogenic (variants of unknown significance), the 
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patient could be having mutations in multiple genes (polygenic) and there could be other 
novel genes which are yet to be discovered (Thomas, 2015). Hence, it is important for 
clinicians and patients to acknowledge that a negative result does not exclude a diagnosis 
of FH. 
1.10 Need for further research and service development 
In the last decade, our understanding of human lipid biology has dramatically increased, 
and novel FH-associated variants continue to be reported world-wide on FH causing 
genes. This consequently imposes practical limitations on our current traditional genetic 
screening methods and therefore there remains no single test that can effectively 
diagnose FH. However, it is of paramount importance to effectively diagnose and detect 
FH at an early stage with relatively low cost in order to prevent CHD and also to tailor 
appropriate management strategies. Recently, few studies have shown that targeted NGS 
approaches can effectively be used in the screening and diagnosis of FH (Futema et al., 
2012) (Vandrovcova et al., 2013).  
NGS and its potential applications in the next few years will bring a huge transition in 
routine molecular diagnostics and hence NHS laboratories should be prepared to 
embrace the technology at the earliest. To do so, more NGS studies will need to be 
carried out in the NHS laboratories to witness the diagnostic potential of NGS as well as to 
aid its translation into routine molecular diagnostics. In addition, by conducting more pilot 
studies using NGS approaches in the laboratories of the NHS will allow the healthcare 
professionals to gain more expertise and competence for successful implementation of 
NGS into routine diagnostics.  
In the current era of genomics, it is necessary for the NHS molecular laboratories to keep 
in pace with the rapid explosion of developments in the NGS technology. Our study will 
serve as a proof of principle study and will aid in understanding the technical challenges 
and barriers in implementing NGS technology into routine molecular diagnostic services of 
the NHS. The future for NGS is highly promising and its use in routine diagnostic 
molecular laboratories can also be expanded into areas beyond FH. 
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1.11 Aims of the study 
 
1) To set up next generation sequencing methodology for the genetic screening of familial 
hypercholesterolaemia. 
2) To validate the next generation sequencing results by comparing it with the reference 
lab results. 
3) To evaluate the technical issues and implementation barriers of setting up the NGS 
methodology in routine molecular diagnostic laboratories of the NHS. 
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CHAPTER TWO 
MATERIALS AND METHODS 
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Materials and methods 
2.1 Ethical approval 
This study was sponsored by the University Hospital Southampton NHS Foundation Trust 
(UHS) under the terms of the Department of Health Research Governance Framework for 
Health and Social Care (Health, 2005). R&D confirmation of capacity and capability 
approval was obtained from UHS R&D. Research ethics committee (REC) approval 
(16/NW/0215) and Health Research Authority (HRA) approval were obtained for this study 
from North West – Greater Manchester South Research Ethics Committee. 
2.2 Sample selection 
University Hospital Southampton NHS Foundation Trust runs a lipid clinic where patients 
with elevated cholesterol and other forms of lipidaemia are being diagnosed, assessed 
and managed. Patients visiting the lipid clinic have either one of the following or a 
combination of the following: elevated blood plasma cholesterol, family history of elevated 
blood plasma cholesterol, coronary heart disease (CHD) and tendon xanthomata. Patients 
with the above conditions and who fulfil the Simon Broome criteria (“Risk of fatal coronary 
heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf 
of the Simon Broome Register Group,” 1991) are referred for genetic testing for FH in a 
reference lab by the Consultant in the lipid clinic. The DNA is extracted and stored from 
these patient samples. Patients identified as having a mutation in one of the FH genes or 
not having a mutation are documented in the patient notes and are managed with 
appropriate prophylactic strategies in UHS. A retrospective cohort of 94 DNA samples 
from patients known to have FH or suspected to have FH was selected for this study. All 
the samples for this study were provided by the Consultant running the lipid clinic at UHS. 
The samples were fully anonymised and no patient identifiable information such as name, 
age, hospital number and gender was available. Details provided were unique identifier 
number for each sample and the type of variant detected by the reference lab along with 
the method or panel used for the detection of the variant. No other information was 
available. 
2.3 Primer design on Illumina DesignStudio 
Illumina® DesignStudio™ (Illumina, 2016a) was used to design the amplicons for the FH-
NGS study. DesignStudio™ is a personalised web based sequencing assay design tool 
used to design, review and order the amplicons for the study. TruSeq® custom amplicon 
is a fully customisable amplicon- based assay for targeted sequencing offered by Illumina. 
TruSeq custom amplicon allows researchers to sequence hundreds of genomic regions 
with little as 2Kb to 650Kb of cumulative sequences. 
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Five main genes (LDLR, APOB, PCSK9, LDLRAP1 and APOE) with mutations known to 
cause FH were added to the DesignStudio to design the amplicons for the study. After 
adding the genes of interest in the DesignStudio, the programme brings up the target 
regions with number of targets, cumulative targets (base pairs), total number of amplicons 
along with their coverage. The UHS design data was reviewed and was found to have low 
coverage in certain regions in LDLR as low as 68% and the overall coverage was 94% as 
shown below in Figure 11. Illumina diagnostics was contacted and the final design was 
optimised by the Illumina concierge team. The FH-NGS panel designed and validated by 
Illumina had an overall coverage of 98% with 211/211 selected amplicons, 68/68 selected 
targets and with a cumulative target of 32,197bp. There was one gap with a gap distance 
of 510bp in the LDLR region 11,241,937 to 11,244,525 which had only 80% coverage. 
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                         Figure 11 Screen shot of Illumina® DesignStudio™. FH-NGS amplicons were designed at UHS on the Illumina® DesignStudio™.             
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2.4 Measuring the DNA concentration 
Quality of DNA is very crucial for a good library preparation. Construction of high quality 
sequencing libraries is very significant for successful NGS. DNA quality and concentration 
was estimated both by Qubit Flourometer and by NanoDrop. Through Qubit Flourometer, 
the interference of contaminants such as degraded DNA/RNA is eliminated and through 
NanoDrop the quality and purity is determined. 
2.4.1 Measuring the DNA concentration by Qubit 
The double stranded DNA concentrations of the anonymised patients sample were 
determined using the next generation benchtop Qubit® 3.0 Fluorometer (Thermo Fisher 
Scientific, 2014). The Qubit Fluorometer utilises florescent dyes that specifically bind to 
the targets even at low concentrations and emits a signal. The Qubit Fluorometer is more 
sensitive than UV absorbance, since it minimises the effect of other contaminants such as 
degraded DNA /RNA. 
The Qubit® Fluorometer was calibrated using Qubit™ dsDNA Broad Range Standard 1 
and 2 before measuring the DNA concentration on the patient samples. A working solution 
was prepared by adding 1µl of Qubit® Broad Range Detection Reagent (fluorochrome) to 
199 µl of Qubit® Broad Range Buffer. 195 µl of the working solution was added to 5 µl of 
the patients DNA sample in Qubit® Assay tubes. The tubes were vortexed for 2-3 sec and 
incubated at RT for 2 min. The tubes were then placed in the Qubit® 3.0 Fluorometer and 
the dsDNA concentration was measured using the dsDNA Broad Range programme. The 
concentrations of dsDNA in the patients sample were documented on a spreadsheet in 
ng/µl. This worksheet was used to work out the dilutions required to prepare a working 
concentration DNA of 25ng/µl. All the patient samples were then diluted individually with 
DNA/RNA free water to have a concentration of 25ng/µl.                   
2.4.2 Measuring the DNA concentration using NanoDrop 
The anonymised samples were also checked for concentration and quality using the 
NanoDrop® ND-1000 Spectrophotometer (Thermo Fisher Scientific, 2010) which can 
analyse the absorbance of RNA, DNA, nucleic acids and proteins. The ratio of 
absorbance at 260nm and 280nm were used to assess the purity of the DNA samples. A 
ratio of ~1.8 was generally accepted as “pure” for DNA and 98% of our study samples had 
a 260/280 ratio greater than 1.8. This technology is also useful for low volume samples. 
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2.5 Illumina workflow 
Illumina MiSeq platform was used in this FH-NGS study which utilises the sequencing by 
synthesis (SBS) principle (Braun & LaBaer, 2003) and is a widely used next generation 
sequencing technology. Illumina platforms support massively parallel sequencing using a 
proprietary method that detects single bases as they are incorporated into the growing 
DNA strand. Illumina workflow includes four basic steps: Library preparation, cluster 
generation, sequencing and data analysis as shown in Figure 12. 
 
Figure 12 Illumina sample workflow. 
 
2.5.1 Library preparation 
Illumina TruSeq Custom Amplicon v1.5 protocol (Illumina, 2016c) was followed to prepare 
the libraries as shown in Figure 13. 94 uniquely indexed paired-end libraries of the 
genomic DNA were prepared using the Illumina® TruSeq® Custom Amplicon Library 
Preparation kit. The TruSeq Custom Amplicon library protocol offers multiplexing 
capability to amplify all the amplicons in a single reaction and sequence them in a single 
run. 
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                   Figure 13 TruSeq Custom Amplicon Workflow (Illumina, 2016c). 
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2.5.2 Hybridize the oligo pool 
This process hybridizes a custom oligo pool which contains the upstream and 
downstream oligos specific to targeted regions of interest as shown in Figure 14. In this 
step the primers anneal to the genomic DNA. Multiple samples can be processed 
simultaneously using the 96 well filter plate. Extreme care should be taken and personal 
protective equipment should be used during this procedure as these sets of reagents 
contain formamide, a reproductive toxin. 5µl of Amplicon Control DNA (ACD1) was added 
to 5µl of distilled water to well one of the Hybridization Plate (HYP). Use of control DNA 
enables the Illumina technical team to troubleshoot in case of any issues with the assay. 
Then 10µl of genomic DNA (25ng/µl) was added to each of the remaining wells 
respectively. Then 5µl of Control Oligo Pool (ACP1) was added to the well containing 
ACD1 and 5µl of Custom Amplicon Oligos (CAT) was added to all the wells containing the 
genomic DNA. The plate was then centrifuged at 1000 x g for 1 min. After centrifuging, 
35µl of Oligo Hybridization for Sequencing 2 (OHS2) was added to each well and mixed 
by pipetting and the plate was again centrifuged at 1000 x g for 1 min. The plate was then 
placed on the preheated heat block and incubated at 40ºC for 80 min. 
 
Figure 14 Hybridization of upstream and downstream oligos to the region of interest. ULSO: 
Upstream Locus-Specific Oligos, DLSO: Downstream Locus-Specific Oligos. 
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2.5.3 Removal of unbound oligos 
This step removes the unbound oligos from the genomic DNA using a size-selection filter. 
The filter plate was assembled as shown in Figure 15. 
                       
Figure 15 Filter Plate Unit (FPU) assembly (Illumina, 2016c). A=Lid, B=Filter plate, C=Adaptor 
collar, D=Midiplate. 
The wells of the filter plate were washed by adding 45µl of Stringent Wash 1 (SW1) to 
each well. The FPU was then covered and centrifuged at 2400 x g for 10 minutes. Care 
was taken to ensure that there was not >15µl/well of residual buffer in the wells. Then the 
plate was removed from the heat block and centrifuged at 1000 x g for 1 min. The 
samples from each well were then transferred to the corresponding well of the FPU plate. 
The FPU plate was covered and centrifuged at 2400 x g for 2 min. The plate was then 
washed twice by adding 45µl of SW1 to each sample well. The plate was covered and 
centrifuged at 2400 x g for 2 min. The plate was centrifuged again to ensure the SW1 had 
drained completely. The flow through was discarded with each wash and 45µl of Universal 
Buffer 1 (UB1) was added to each sample well and covered. The plate was then 
centrifuged at 2400 x g for 2 min. The plate was centrifuged for further few minutes to 
ensure UB1 had drained completely. 
2.5.4 Extend and ligate bound oligos 
This step connects the hybridized upstream and the downstream oligos. A DNA 
polymerase extends from the upstream oligos through the targeted region, followed by the 
ligation to the 5’ end of the downstream oligo using a DNA ligase as shown in Figure 16. 
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This results in the formation of products containing targeted regions of interest flanked by 
sequences required for amplification.   
45µl of Extension-ligation Mix 4 (ELM4) was added to each sample well of the FPU plate. 
The plate was sealed using foil adhesive seal and incubated at 37ºC for 45 min. 
 
Figure 16 Extension and ligation of bound oligos. ULSO: Upstream Locus-Specific Oligos, 
DLSO: Downstream Locus-Specific Oligos. 
2.5.5 Amplify Libraries 
This step amplifies the extension-ligation products and adds the index 1 (i7) adapters, 
index 2 (i5) adapters and sequences required for the cluster formation as shown in Figure 
18. By multiplexing, large number of libraries can be pooled and can be sequenced in a 
single sequencing run. 
The index 1 (i7) adapters and the index 2 (i5) adapters were arranged on the TruSeq 
Index Plate Fixture in columns 1-12 and rows A-H as shown in Figure 17. 
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Figure 17 TruSeq Index Plate Fixture (Illumina, 2016c). A= Rows A-H: Index 2 (i5) adapters 
(white caps), B= Columns 1-12: Index 1 (i7) adaptors (orange caps), C= Indexed Amplification 
Plate (IAP) plate. 
The plate was then placed on the TruSeq Index Plate Fixture and 4µl of each Index 1 (i7) 
adapter was added down to each column using a multichannel pipette. Then 4µl of each 
index 2 (i5) adapters was added across each rows using a multichannel pipette. New 
orange and white caps were used to recap the unused indexes to avoid cross 
contamination. Then the FPU plate from the incubator was removed and the aluminium 
foil seal was replaced with the filter plate lid. The plate was then centrifuged at 2400 x g 
for 2 min. After centrifugation, 25µl of freshly made 50 mM NaOH was added to each well 
and mixed well with a pipette. The plate was then incubated at RT for 5 min. This step 
removed the bound libraries from the filter plate. PCR master mix 2 (PMM2) and TruSeq 
DNA Polymerase 1 (TDP1) mixture was prepared freshly just before use by combining 
56µl TDP1 to a full tube (2.8ml) of PMM2 and mixed well by inverting. Then 22µl of 
PMM2/TDP1 mixture was added to each well of the IAP plate. Then 20µl of the eluted 
samples from the FPU plate was transferred to the IAP plate and mixed well with a 
pipette. The waste collection in the midi plate was discarded. The IAP plate was then 
centrifuged at 1000 x g for 1 min. After centrifugation, the IAP plate was taken to the post-
amplification area and placed on a thermal cycler to run the PCR. The plate was left on 
the thermal cycler at 95ºC for 3 min and then the PCR was run for 25 cycles at 95ºC for 
30 sec, 66ºC for 30 sec, 72ºC for 60 sec. After the 25 cycles the plate was programmed to 
incubate at 72ºC for 5 min and then held for infinite at 10ºC on the thermal cycler. 
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Figure 18 Sample indexing and amplification. ULSO: Upstream Locus-Specific Oligos, DLSO: 
Downstream Locus-Specific Oligos. 
2.5.6 Quality, quantification and sizing of the amplified libraries 
The amplified library quality, quantification and sizing were performed both by the gel 
electrophoresis and by the Bioanalyser method. 
2.5.6.1 Gel electrophoresis method 
2% Agarose gels were prepared using 2g of agarose powder (Alpha Laboratories) in 
100ml of Tris Acetate-EDTA (TAE) buffer. The gel was supplemented with ethidium 
bromide (Sigma) (final concentration of 0.5µg/ml) before pouring the gel. The gel was 
poured on the plate with combs in place and was allowed to settle at RT for 1h. Then the 
combs were removed and the gel was placed in the electrophoresis tank with TAE buffer 
along with 1-2µl of ethidium bromide. To visualise the amplified libraries, 10µl of the 
samples were added to 1-2µl of the loading dye and electrophoresed at 100 volts for 
40min-1hour. The patient samples were run along with a 100bp ladder to visualise the 
size of the products as shown in the Figure 19. Expected PCR product size around 350bp 
for 250bp amplicons were seen on both the gel electrophoresis as well as on the 
Bioanalyser. 
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Figure 19 Gel electrophoresis of amplified libraries along with 100bp ladder. Amplicons of 
size 350bp were seen on the gel electrophoresis post PCR. 
2.5.6.2 Bioanalyser method 
The amplified libraries were also run on a Bioanalyser (Agilent Technologies, 2007) 
according to the manufacturer’s instructions to assess the quality, quantity and the size. 
Agilent DNA 1000 assay protocol was followed in running the Bioanalyser. The gel-dye 
mix was prepared by adding 25µl of DNA dye concentrate to the DNA gel matrix vial and 
vortexed to mix well. The vial was then centrifuged at 2240 x g for 15 mins and then 
stored at 4ºC and protected from light. Expected PCR product size around 350bp for 
250bp amplicons were seen on the Bioanalyser as shown in Figure 20. Bioanalyser was 
used to accurately quantify and assess the quality and size of the amplified libraries which 
is significant for further downstream analysis. It also allows visualisation other unwanted 
products present in the sample. 
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Figure 20 Amplified libraries along with a ladder on a Bioanalyser. TSCA: TruSeq Custom 
Amplicon. 
 
2.5.7 Clean up Libraries 
AMPure XP beads (Beckman Coulter, 2016) were used in this step to purify the PCR 
products from other reaction components as shown in Figure 21. These are paramagnetic 
beads which acts like a magnet in a magnetic field. 
 
          Figure 21 Library clean up using AMPure XP beads (Beckman Coulter, 2016). 
45µl of AMPure XP beads (for amplicon size 250bp) were added to each well of a new 
midi plate and labelled as Cleanup Plate (CLP). All the supernatant from the IAP plate 
were transferred to the corresponding well of the CLP plate. The plate was shaken at 
1800 rpm for 2 min and then incubated at RT for 10 min. The PCR products bind to the 
paramagnetic beads. The plate was then placed on a magnetic stand for approximately 2 
min until the liquid was clear.  This step aids in the separation of beads bound to the PCR 
products from other contaminants. All the supernatant from each well was removed and 
discarded. 40ml of fresh 80% ethanol was prepared from 100% ethanol for 96 samples. 
The CLP plate was washed 2 times by adding 200µl of 80% ethanol to each sample well 
and incubating on the magnetic stand for 30 sec to remove all the contaminants. The 
supernatant was removed and discarded after each wash with 80% ethanol. The residual 
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ethanol was removed from each well by using a 20µl pipette. The plate was then removed 
from the magnetic stand and air dried at RT for exactly 10 min. The plate should be dried 
exactly for 10 min only at RT, as prolonged air drying could lead to cracking of beads. 
After air drying 30µl of Elution Buffer with Tris (EBT), was added to each well and shaken 
at 1800 rpm for 2 min. Care was taken to ensure that all the beads are suspended after 
shaking. This step washes all the DNA from the beads when incubated at RT for 2 min. 
After incubation, the plate was placed on the magnetic stand for approximately 2 min until 
the liquid was clear. 20µl of the supernatant from each well of the CLP plate were then 
transferred to the corresponding well of the Library Normalization Plate (LNP) and 
centrifuged for 1000 x g for 1 min. 
2.5.8 Normalize Libraries 
This step normalizes the quantity of each library for balanced representation in pooled 
libraries. Library normalization ensures all samples are represented equally. During this 
normalization procedure, DNA binds to the beads in approximately the same 
concentration in all the samples and yields the same concentration across all samples 
when eluted. After normalization, the final sample is single stranded which can be loaded 
on the MiSeq analyser.  
A Library Normalization Additives 1 (LNA1) and Library Normalization Beads 1 (LNB1) 
mixture was prepared just before use by adding 4.4ml of LNA1 to 800µl LNB1 in a 15ml 
conical tube. The tube was inverted several times to prepare the LNA1/LNB1 mixture. 
45µl of LNA1/LNB1 mixture was added to each well of the LNP plate and shaken at 1800 
rpm for exactly 30 min, as any other duration other than 30 min will affect the library 
representation and cluster density. After 30 min the plate was removed from the shaker 
and placed on a magnetic plate for approximately 2 min until the liquid was clear. All the 
supernatant was then removed and discarded. The plate was then removed from the 
magnetic plate and washed twice by adding 45µl of Library Normalization Wash1 (LNW1) 
to each well and shaking the plate at 1800 rpm for 5 min. After shaking for 5 min the plate 
was placed on the magnetic plate for 2 min until the liquid was clear. The supernatant was 
removed and discarded after each wash. The residual LNW1 was removed from each well 
using a 20µl pipette. The plate was removed from the magnetic plate and 30µl of freshly 
made 0.1N NaOH was added to each well and shaken at 1800 rpm for 5 min for 
suspending the libraries. The LNP plate was then placed on the magnetic plate for 2 min 
until the liquid was clear. For storage 30µl of Library Normalization Storage Buffer 2 
(LNS2) were added to a plate labelled as Storage Plate (SGP) and 30µl of supernatant 
from each well of the LNP plate was transferred to the corresponding well of the SGP 
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plate. The plate was then centrifuged at 1000 x g for 1 min and stored at -25ºC to -15ºC 
(stable for 30 days) until the libraries were pooled. 
2.5.9 Pool Libraries 
Pooling libraries combines equal volumes of normalized libraries in a single tube. This 
pool is later diluted and denatured for the sequencing run. 5µl of each library is transferred 
to an 8-tube strip, column by column to form a pool. The contents of the 8-tube strip were 
transferred to a Pooled Amplicon Library (PAL) Eppendorf tube. This PAL tube can be 
frozen at -25ºC to -15ºC and stable for 30 days. 94 samples were done in three batches 
and all the 3 library pools were pooled together to form a single library pool and was 
frozen at -25ºC to -15ºC. 
2.5.10 Denaturing and diluting the libraries 
For denaturing and diluting the libraries, Protocol B: Bead based normalization method in 
the Illumina document #15039740 v01 was followed (Illumina, 2016b). The Hybridization 
Buffer (HT1) was removed from the -25ºC to -15ºC freezer and thawed at room 
temperature. After thawing the HT1 was stored at 2ºC to 8ºC. The library was then diluted 
to the loading concentration by adding 8µl of amplicon library pool to 592µl of prechilled 
HT1 to make a total volume of 600µl in a micro centrifuge tube. This was briefly vortexed 
for 1 minute at 280 x g. PhiX serves as a control adapter-ligated library in the sequencing 
run and provides quality metrics for cluster generation, sequencing, alignment, phasing 
and pre-phasing (Illumina, 2016d). 
The diluted library was placed in the incubator for 2 min at 98ºC. After 2 min, the micro 
centrifuge tube was removed from the 98ºC incubator and immediately cooled by placing 
the micro centrifuge tube on ice for 5 min.  
The PhiX Control was denatured and diluted to 12.5pM to produce an optimum cluster 
density for v2 Illumina reagents. PhiX was diluted to 4 nM by combining 2µl of 10 nM PhiX 
library to 3µl of 10 nM Tris-Cl at pH 8.5 with 0.1% Tween 20. PhiX Control was denatured 
by combining 5µl of 4 nM PhiX library with 5 µl of freshly prepared 0.2N NaOH in a micro 
centrifuge tube. The mixture was briefly vortexed and centrifuged for 1 minute at 280 x g 
and incubated at room temperature for 5 min. The denatured PhiX was diluted to 20 pM 
by adding 10µl of denatured PhiX library to 990µl of pre chilled HT1which results in 1ml of 
20 pM PhiX library. This was further diluted to 12.5 pM PhiX by mixing 375µl of 20 pM 
denatured PhiX library to 225µl of pre chilled HT1 which results in 600µl of 12.5 pM PhiX 
library.  
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A low concentration PhiX control spike-in of 1% was used as a sequencing control which 
was prepared by combining 6µl of denatured and diluted PhiX with 594µl of denatured 
and diluted library. This mixture was placed on ice to be loaded onto the reagent cartridge. 
2.5.11 Creating sample plate, sample sheets and manifest file on Illumina 
experiment manager (IEM) software 
IEM is a software programme used in creating and editing sample sheets for Illumina 
instrument and analysis. A sample sheet was created using IEM which involved two steps. 
Initially, a sample plate was created which included information about samples in each of 
the 96 wells, type of library that was performed, plate name and the sample indexes used. 
Secondly, the sample sheet was created based on the sample plate information which 
passes the information on the run and samples in the correct (.csv) file format to the 
instrument and the analysis software. While creating the sample sheet, care was taken to 
ensure correct barcode details of the reagent cartridge, type of kit, number of indexes, 
name of the experiment, name of the investigator and date were being entered.  
A manifest file was created which contained information about each sample that focuses 
analysis results only to user-defined regions of interest, information on the reference 
genome used for alignment, information on Chromosome coordinates i.e. start and stop of 
each amplicon used and the length of the PCR primer used for the generation of the PCR 
amplicon. 
2.5.12 MiSeq flow cell 
MiSeq flow cell is a single use glass based substrate where the clusters are generated 
and the sequencing reaction is performed. The reagents enter the flow cell through the 
inlet port and pass through the imaging lane and exists the flow cell through the outlet 
port. The waste from the flow cells goes to the waste bottle.                                            
2.5.13 Illumina reagent cartridge 
Illumina MiSeq reagent cartridge is a single use cartridge consisting of foil-sealed 
reservoirs consisting of reagents for cluster generation and sequencing for 1 flow cell. The 
reservoirs on the cartridge are numbered and the sample libraries are loaded on the 
cartridge on reservoir number 17, which is labelled as “Load Samples”. Libraries were 
loaded on the Illumina reagent cartridge and analysed according to the manufacturer’s 
instructions.    
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2.6 Monitoring the run on BaseSpace 
MiSeq run monitoring was performed using Sequencing Analysis Viewer (SAV) in 
BaseSpace as shown in Figure 22. BaseSpace is a cloud based genomics computing 
environment for analysing, storing next generation sequencing data. Sequencing labs can 
store and share data as well as monitor sequencing runs on the Illumina analysers in real 
time. BaseSpace also offers a wide variety of NGS data analysis applications including a 
few third party applications. Using BaseSpace, one can remotely monitor a sequencing 
run, cluster Intensity, Q-Score, cluster density, clusters passing through the filter and the 
estimated yield. The FH-NGS run in Figure 23 and 24 shows lane metrics and graphs on 
flow cell chart, data by cycle, data by lane, QScore distribution and QScore heatmap. 
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Figure 22 Sequencing Analysis Viewer (SAV) on BaseSpace. Screen shot of the FH run summary on BaseSpace.
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Figure 23 Screen shot of the charts on the FH run on BaseSpace.                                                                       
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Figure 24 Run and Lane metrics of the FH-NGS run.                                                                   
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The run lane metrics gives more detailed information about the run. It gives information on 
the read 1 and 2 along with the number of cycles, yield, percentage of aligned reads, error 
rate in percentage, Q30 in percentage, cluster density (K/MM2), percentage of clusters 
passing through the filter, number of reads passing through the filter etc. 
2.7 Bioinformatic analysis 
Bioinformatic analysis is a process of analysing and interpreting complex genomic data 
using computer software tools. It is a complex stepwise process which involves the 
application of computational techniques to design a pipeline which aids in identification of 
pathogenic variants from raw genomic data. First step involved determining the quality of 
raw reads and bases. Poor quality reads and bases were trimmed at the 3’ end. After 
quality checks, the reads were aligned to the reference genome for variant calling. Finally 
the data was annotated to filter and identify the pathogenic variants. 
2.7.1 BaseSpace analysis 
FH-NGS data was analysed on Illumina BaseSpace and the data analysis workflow 
consists of two main phases: 1) Primary analysis and 2) Secondary analysis.  
During the primary analysis, the images were analysed for base calling after intensity 
extraction and correction. The initial sequencing output files from the MiSeq analyser were 
Tagged Image File Format (*.tiff). MiSeq control software analyses the images in real time 
and after analysis the images are deleted since the file sizes are very big and require 
large storage space. The tiff files are converted and saved as Cluster Intensity Files (*.cif). 
Base calling is performed as soon as image analysis is completed. Cluster intensity files 
are converted to Base Calling Files (*.bcl) which are converted to *.fastq files which 
contain information about the read, sequence of the read etc. 
During the secondary analysis, the MiSeq reporter software processes the base calls 
generated during the primary analysis and also aids in alignment and variant calling. The 
output files are in .fastq.gz, .bam, and .vcf formats. .fastq.gz is a text based file format for 
storing nucleotide sequence and its corresponding quality scores. Binary Compressed 
Sequence Alignment/Map (.bam) file contains information on aligned reads and the 
Variant Call Format (.vcf) file contains information about variant calls.   
Fastq files were loaded on the BaseSpace and the variant calling was performed. On 
completion, detailed information was available on BaseSpace on i) amplicon summary 
statistics was available both at read level and base level ii) small variants summary 
statistics with SNV’s, insertions and deletions and iii) coverage summary with amplicon 
mean coverage depth for each sample. 
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i) Amplicon summary statistics: The amplicon summary report detailed 
statistical information on all samples at a) Read level and at the b) Base level. 
a) Read Level Statistics  
Read level statistics report details information on each sample with total 
aligned reads (R/R2) i.e. the total count of PF (passing filter) reads aligning 
for the sample (Read1/Read2), statistical information on percent aligned 
reads (R1/R2) i.e. percentage of PF reads aligning for the sample 
(Read1/Read2), and statistical information on overall percent aligned reads 
i.e. percentage of PF reads aligning for the sample across both reads 1 
and 2 as shown in Figure 25. 
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Figure 25 Read level statistics along with percentage of aligned reads. 
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b) Base level statistics 
Base level statistics report details statistical information on total number of 
bases aligning for the sample (Read1/Read2), information on overall total 
aligned bases i.e. the total count of bases aligning for the sample across both 
reads 1 and 2, statistical information on percent aligned bases (R1/R2) i.e. 
percentage of bases aligning for the sample (Read1/Read2), statistical 
information on overall percent aligned bases for sample across both reads 1 
and 2, statistical information on the percentage of bases with a quality score of 
30 or higher for read 1 and 2, information on mismatch rate i.e. percentage of 
mismatch to reference averaged over cycles per read (Read1/Read2) as 
shown in Figure 26. 
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Figure 26 Base level statistics along with percentage of aligned bases. 
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ii) Small variants summary statistics  
The small variants summary statistics report detailed information on a) SNVs, 
b) Insertions and c) Deletions. 
a) SNVs: SNVs statistics report detailed information on the total number of 
SNVs which passed through the quality filter which ranged from 28 to 68 as 
shown in Figure 27. 
b) Insertions: The insertions statistics report detailed information about the 
number of insertions present in the dataset which passed the quality filter 
as shown in Figure 28. 
c) Deletions: The deletions statistical report on the dataset detailed 
information about the total number of deletions passing through the quality 
filters as shown in Figure 29. 
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Figure 27 Small variants summary along with the number of SNVs passing through the filter. 
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Figure 28 Insertions statistics report with number of insertions passing through the filter. 
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Figure 29 Deletions statistics report along with number of deletions passing through the filter. 
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iii) Coverage summary: The coverage summary of the dataset details information on the amplicon mean coverage depth as shown in 
Figure 30.
 
Figure 30 Coverage summary.  
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BaseSpace also creates a PDF summary report for each sample analysed as shown in 
Appendix 6. The PDF summary report includes detailed sample information which 
includes total number of reads passing the filter and percentage Q30 score, amplicon 
summary which includes the number of amplicon regions, total length of amplicon regions. 
The PDF summary report also details information on read level statistics which includes 
information on total number of aligned reads for 1 and 2 along with the percentage of 
aligned reads. At base level statistics it includes information on percent Q30 bases, total 
number of aligned bases, percentage of aligned bases out of the total bases and the 
mismatch rates for read 1 and 2. The PDF report generated also provides information on 
the small variants summary with total number of SNV’s, insertions and deletions. The 
report also classifies the variants further in detail with number of variants at gene level, in 
the exonic level, coding regions, UTR regions and in splice site regions and also further 
classifies variants by their consequences i.e. frameshift, non-synonymous, synonymous, 
stop gained and stop lost etc. The coverage summary in the report includes information 
on amplicon mean coverage and uniformity of coverage both in tabulated and graphical 
versions. 
2.7.2 BaseSpace Variant Interpreter Beta 
This is a cloud-based platform offered by Illumina for interpreting and reporting genomic 
variants. This was used to see if there were any differences in the variant calling. It also 
decreases the time and effort in designing complicated pipelines. VCF files were uploaded 
along with the sample number, gender of the patient and other identifications. Once 
submitted the data are imported and analysed. BaseSpace Variant Interpreter Beta 
platform generates a report with the total number of variants. The variants can be filtered 
generally based on prediction if they are pathogenic, likely pathogenic, benign and based 
on the zygosity and genomic regions. Filtering of variants can also be performed based on 
population frequency, annotation data bases, consequences and impact etc. Figure 31 
shows identification of a pathogenic LDLR variant on Illumina Variant Interpreter Beta. 
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Figure 31 Pathogenic LDLR on the Illumina Variant Interpreter Beta. 
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2.7.3 Galaxy 
Galaxy (Blankenberg, Kuster, et al., 2010) is a web-based, open source platform which 
was used to perform the bioinformatics analysis for this study. This was used in addition to 
BaseSpace, to identify if there were any differences in variant calling and to avoid biases. 
Special training was undertaken to use this platform as a part of the Genomic Medicine 
course. The platform also provides detailed auditable information on the bioinformatic 
analysis. The history bar on the Galaxy analysis platform shows an audit of steps 
undertaken to manipulate and analyse the data. A pipeline was specially designed and 
constructed for the FH-NGS study as shown in Figure 37 by adding the analysis tools in a 
step by step process as shown below.  
1) Input data sets: The first step of the pipeline was to input the Fastq raw data for 
read 1 and 2. There are options to upload files from local disk or from the web. As 
soon as the data is uploaded, the file formats can be auto-detected or manually 
assigned.  
2) FastQC: Once the raw reads were uploaded, a quality check was performed on 
the sequences by FastQC (Andrews, 2010). The aim of this step was to get an 
idea on the quality of reads and to establish if the reads were of expected quality 
before performing the analysis. The main function of FastQC is to provide a quick 
overview of the quality and areas where there could be problems. It summarises 
the findings on the basic statistics, per base sequence quality, per base sequence 
quality scores, per base sequence content, per base GC content, per sequence 
GC content, sequence length distribution, per base N content i.e. base calls which 
could not be made with certainty, sequence duplication levels etc. Quality scores 
were derived from the PHRED programme. This programme reads DNA 
sequences and assigns quality scores to each base using the formula shown 
below. 
 
Q_PHRED = -10 log 10 (Pe) 
 
Pe = error in base calling. All of the quality scores are stored in a file called QUAL, 
which has a header line followed by integers. Low integers indicate probability of 
the bases being called incorrectly and higher scores indicates the probability of 
increased accuracy in base calls. 
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Table 2 PHRED score table. 
PHRED Quality Score Probability of incorrect 
base call 
Base call accuracy 
10 1 in 10 90% 
20 1 in 100 99% 
30 1 in 1000 99.9% 
40 1 in 10000 99.99% 
50 1 in 100000 99.999% 
 
 
Figure 32 Range of quality scores over all reads at each position. Quality metrics are reported 
using a traffic light warning system, normal (green), abnormal (orange) and bad (red). Quality 
scores across all the bases are in the green region indicating they are good quality data.  
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Figure 33 Average quality scores over all reads. Quality metrics indicates the mean sequence 
quality is well above Q30 indicating good quality data. A mean quality score below 27 indicates to 
0.2% error rate and score below 20 equate to 1% error. 
3) FASTQ joiner: In this step paired end FASTQ reads from two separate files are 
joined into a single read in one file using the FASTQ joiner tool (Aronesty, 2013). 
The joining is performed using sequence identifiers and if they are not present in 
both the files they are excluded from the output. 
4) Filter by quality: This tool filters the reads based on their quality scores. The 
quality cut-off value and percent of quality bases in the sequence are assigned so 
that any reads below the assigned quality will be filtered. 
5) FASTQ splitter: This tool splits a single fastq data set representing a paired end 
run into two data sets (Blankenberg, Gordon, et al., 2010). This tool works only 
when both the reads are of same length. 
6) Map with BWA-MEM: This alignment algorithm tool is used to align the 
sequences against a reference genome (H Li & Durbin, 2009) (Heng Li & Durbin, 
2010). NGS experiments generate millions of small reads which need to be 
aligned or mapped to the reference genome. Using the standard alignment 
algorithms for millions of reads is time consuming and not feasible. Burrows-
Wheeler Alignment (BWA) is generally used for DNA projects and performs 
gapped alignments. BWA is most widely used, but its mapping algorithms are least 
understood. This tool has a greater power to determine indels and SNPs. BWA 
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automatically chooses between local and end to end alignments, supports paired-
end reads. This algorithm is robust to sequencing errors and is best suited to read 
lengths greater than 70 bp. This tool takes in fastq files as the input files and the 
produces the output files in BAM format. 
7) FASTQC: This tool is used to perform the quality checks.  
8) Flagstat: This tool tabulates descriptive statistics for the BAM dataset by using 
samtools flagstat (H Li et al., 2009) as shown below. 
 
9) Filter SAM or BAM, output SAM or BAM: This tool filters a SAM or BAM file on 
the mapping quality, FLAG bits, read group, library or region. The input file type is 
SAM or BAM format and the output will be SAM or BAM based on the chosen 
option. 
10)  Flagstat: This tool uses samtools flagstat command to tabulate descriptive stats 
for BAM dataset. 
11)  IdxStats: This runs samtools idxstats command to tabulate mapping statistics for 
BAM dataset (H Li et al., 2009). The input file is a sorted and indexed BAM file and 
the output is tabular with four columns representing reference sequence identifier, 
reference sequence length, number of mapped reads and number of placed but 
unmapped reads as shown in Figure 34. 
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                             Figure 34 Screen shot of output table from IdxStats 
12) Add or replace read groups: This tool adds or replaces read group information in 
an input BAM or SAM files. Setting read groups correctly can simplify the analysis 
greatly as multiple BMA files can be merged into one which will significantly reduce 
the number of steps in the analysis. 
13) Collect insert size metrics: This tool reads a SAM or BAM dataset and creates a 
file with metrics containing statistical distribution of insert sizes and generates a 
histogram plot as shown in Figure 35. 
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Figure 35 Histogram of the insert sizes for all reads.  
14) Depth of coverage: Depth and breadth of sequence coverage is very significant 
for the identification as well as to accurately call the variants. In this step a set of 
BAM files are processed to establish coverage at different levels. Coverage is 
analysed per locus, gene or in total. Coverage can also be determined per sample 
and read group and can be summarised by mean, median and by percentage of 
bases covered etc. The input files are BAM format and the output files are in tables 
(Blankenberg, Kuster, et al., 2010). 
15)  Unified Genotyper: This variant caller calls SNP and indels by using a general 
Bayesian framework (DePristo et al., 2011) (Blankenberg, Kuster, et al., 2010). 
GATK accepts an aligned BAM file as input file and the output files are in VCF 
formats. It also generates some metrics about the base calls with number of visited 
bases along with percentage of callable bases as shown below. 
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16) ANNOVAR Annotate VCF: Annovar was used to annotate each variant in the 
VCF file in respect to their location in genes and coding sequences (K. Wang, Li, & 
Hakonarson, 2010).  In Galaxy, ANNOVAR works only with hg19 VCF files and 
hence they had to be changed from hg_g1k_v37 to hg19. The input file is a VCF 
file format and the output file is a table of annotations for the variants in the VCF 
data as shown in Figure 36.  
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Figure 36 List of variants in the vcf file on Galaxy. 
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17) Text reformatting: This tool runs the unix awk command on the ANNOVAR vcf 
data and the output file is tabular data with a list of variants. 
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Figure 37 FH-NGS Galaxy pipeline for annotation, filtering, alignment and variant calling.  Pipeline designed for use in Galaxy. A PDF link is provided in 
appendix 5 to enable viewing at a higher resolution.
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2.7.4 wAnnovar 
wAnnovar is an online web-based tool to annotate variants obtained from high-throughput 
sequencing. This was used since it was simple and easy and also to see if any new 
variants were called in comparison to BaseSpace and Galaxy. This web- based tool 
required basic information i.e. e-mail address of the person performing the analysis, 
sample identifier, input file (VCF), name of the disease/phenotype and reference genome 
etc. On completion of analysis, a link is sent to the provided e-mail address with a list of 
variants. 
2.8 Sanger Sequencing  
Sanger sequencing was performed on five samples which had discordant results with the 
reference lab results. 
2.8.1 PCR primers 
The PCR primers used for Sanger sequencing were as described in the literature (Lee et 
al., 1998) (Whittall et al., 2010). The primers were supplied by Eurofins Genomics 
(Eurofins Genomics, 2017) as shown in the Table 3. The forward and the reverse primers 
were diluted with DNase free and RNase free water to a stock standard concentration of 
100 pmol/µl. The stock primers were further diluted to working standard concentration of 
5pmol/µl. 
Table 3 Primer sequences used for Sanger Sequencing. 
Gene Exon Primer Sequence (5’→3’) 
LDLR Exon 4 Upstream GGACAGTAGCCCCTGCTCG 
LDLR Exon 4 Downstream GGAGCCCAGGGACAGGTGATAG 
LDLR Exon 14 Upstream GAATCTTCTGGTATAGCTGAT 
LDLR Exon 14 Downstream GCAGAGAGAGGCTCAGGAGG 
 
2.8.2 Initial PCR amplification 
The target region of the LDLR gene was amplified using polymerase chain reaction 
(PCR). The products were prepared in a 25µl reaction with 5U/µL Taq polymerase 
(Thermo Start), 10x reaction buffer, 25 mM MgCl2 (ThermoScientific), 2mM dNTP’s 
(ThermoScientific) and a working concentration of 5pmol/µl of each primer (Eurofins 
Genomics). The PCR was run on G-Storm PCR thermal cycler for 35 cycles of 95ºC for 30 
sec, 68ºC for 30 sec, 72ºC for 1 min and a final extension of 72ºC for 5 min. The PCR 
products were run on an agarose gel and PCR products at the expected sizes of around 
250bp were seen as shown in Figure 38. 
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Figure 38 Electrophoretic gel displaying PCR products. 
                      
2.8.3 DNA Sequencing 
 
2.8.3.1 Purification of PCR products by Qiagen MinElute kit 
The MinElute system (Anon, 2008) was used in purification of the PCR products. It uses 
spin-column technology and selective binding properties of specially designed silica 
membrane to yield high end-concentrations of DNA fragments. DNA adsorbs to the silica 
membrane in the presence of high salt concentration leaving the contaminants to drain 
through the column (Anon, 2008). DNA was eluted according to the manufacturer’s 
instructions using the Qiagen MinElute kit. 
2.8.3.2 Sequencing PCR reaction 
Using ABI’s BigDye Terminator v1.1 cycle sequencing kit (Thermo Fisher Scientific, 
2016), sequencing PCR was set up for 20µl, with 4µl of BigDye sequencing reaction mix 
(Applied Biosystems), 2µl of 5 X dilution buffer (Applied Biosystems), 2µl of the respective 
sequencing primers (5pmol/µl) (Eurofins Genomics), 2µl of purified PCR product and 10µl 
of distilled water. The sequencing PCR was run on G-Storm PCR thermal cycler for 25 
cycles at 96ºC for 10 sec, 50ºC for 5 sec, and a final extension of 60ºC for 4 min. 
2.8.3.3 Dye-Terminator removal 
Dye-Terminator was removed using QIAGEN’s DyeEx 2.0 spin kit (QIAgen, 2012). The 
spin columns were vortexed to re-suspend the resin and DNA was eluted according to 
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manufacturer’s instructions. After centrifugation, the columns were discarded and the 
eluate contained purified DNA. The eluted DNA (20µl) was then transferred to a 96 well 
plate and dried at 70ºC for 1-2 hrs using the PCR machine block. After drying, 10µl of HiDi 
Formamide (Applied Biosystems) was added to each well. The DNA was denatured into 
single strands at 94ºC for 5 min and then cooled to 4ºC using the PCR machine block. 
2.8.4 Sequencing electrophoresis 
Sequencing electrophoresis was carried out on Applied Biosystems Hitachi 3500xL 
Genetic Analyser. The plate records were set up on the analyser with the folder name as 
FH-NGS under the sequencing folder. The plate was then loaded on the analyser and the 
plate record was linked to the plate and the run was started. On completion of the run, the 
sequences were loaded on the Mutation Surveyor® DNA Variant Analysis software 
(Minton, Flanagan, & Ellard, 2011) for mutation identification.
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3. Results 
A retrospective cohort of 94 DNA samples were analysed on Illumina MiSeq analyser. 
These samples were previously analysed by the reference lab by standard molecular 
diagnostic techniques. The reference lab samples had three distinct patterns i.e. 1) 36 
samples were analysed by Bristol Panel, 2) 27 samples were analysed by the FH20 chip 
and 3) for the remaining 31 samples it was not specified by which methodology they were 
analysed. The reference lab had offered an FH service using Bristol panel which 
consisted three levels of analysis. Level 1 consisted sequencing all 18 exons plus 
promotor regions of the LDLR gene, exon 26 hotspot of the APOB, exon 7 of the PCSK9 
along with MLPA analysis of all 18 exons and promotor regions of the LDLR gene. Level 2 
services consisted extended analysis with sequencing of exons 1-6 and 8-12 of the 
PCSK9 gene and level 3 services consisted of Cascade/familial mutation testing. 
Elucigene FH20 kit was being used to detect the most common FH variants in specific 
populations and was designed to replace the comprehensive genetic analysis (Sharma et 
al., 2012). Elucigene FH20 kit detected point mutations, insertions or deletions in the 
LDLR, APOB and PCSK9 genes and the kit was designed only to detect the 20 
commonest mutations which were found in the UK population.  FH 20 is now obsolete and 
is not commercially available since they were able to detect only 20-50% of FH causing 
variants and also was not recommended for cascade testing relatives of people with 
confirmed FH. It was also not found to be cost effective when compared to the 
comprehensive genetic analysis with greater QALY gains and was withdrawn from the 
NICE diagnostic guidance (Sharma et al., 2012). 
3.1 Reference lab findings 
Out of 94 samples, a total of 36 patients had FH variants detected in their samples and 
the remaining 58 patients had no variants identified in their samples as shown in Table 4. 
Table 4 Reference lab findings. 
Ref lab Positive Negative 
31 Samples (Unknown 
source) 24 7 
FH 20 (27 samples) 0 27 
Bristol panel (36 samples) 12 24 
TOTAL 36 58 
                  Positive= FH variants detected, Negative= FH variants were not detected. 
3.1.1 Spectrum of FH variants in the reference lab samples 
The spectrum of FH variants identified in the 94 samples by the reference lab are 
summarised in the Table 5. 17 patients had FH variants detected in the LDLR gene, 17 
patients had FH variants in their APOB gene and 1 patient had a FH variant in the PCSK9 
79 
 
gene. No variants were detected in the LDLRAP1 and APOE genes. 1 patient had FH 
variants detected in both LDLR and APOB genes. 
Table 5 Spectrum of FH variants in the reference lab findings. 
Ref lab LDLR APOB PCSK9 APOE LDLRAP1 
LDLR + 
APOB 
31 Samples 
(Unknown source) 10 14 0 0 0 0 
FH 20 (27 
samples) 0 0 0 0 0 0 
Bristol panel (36 
samples) 7 3 1 0 0 1 
LDLR: Low density lipoprotein receptor, APOB: Apolipoprotein B, PCSK9: Proprotein 
convertase subtilisin/kexin type 9, APOE: Apolipoprotein E, LDLRAP1: Low density 
lipoprotein receptor adaptor protein 1. 
3.2 BaseSpace findings at UHS 
The bioinformatic analysis on BaseSpace at UHS yielded a huge number of variants 
across all the major FH causing genes. These data were tabulated on a MS Excel 
spreadsheet and were also compared against the reference lab findings as shown in 
Appendix 5. Out of the 94 samples analysed, BaseSpace analysis detected 62 patients 
with FH variants whilst 32 patients had no FH variants detected in their samples as shown 
in Table 6. 
Table 6 UHS BaseSpace findings. 
UHS Positive Negative 
31 Samples 
(Source unknown) 28 3 
FH20 (27 Samples) 12 15 
Bristol (36 
Samples) 22 14 
TOTAL 62 32 
Positive= FH variants detected, Negative= FH variants were not detected. 
3.2.1 Spectrum of variants identified by BaseSpace 
FH variants were detected in 62 of 94 patients. A total of 426 variants were identified in 
LDLR gene, 493 variants in APOB gene, 486 variants in PCSK9 gene and 7 variants in 
LDLRAP1 gene. In the 62 patients with FH variants, 40.4% of them were coding missense 
variants, 9.4% were coding synonymous variants, 5.6% were intronic variants, 0.9 % was 
coding frame shift variants and 0.9% was coding stop gained variants. 
3.2.2 Pathogenic FH variants identified through BaseSpace 
A total of 32 FH variants were detected in the LDLR gene of which 17 patients had known 
pathogenic FH variants and 15 patients had variants whose pathogenicity was unknown 
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or had conflicting reports of their pathogenicity as shown in Table 7. In addition, 18 
patients had FH variants detected in APOB gene, 14 patients had FH variants detected in 
their APOE gene and 1 patient had a known FH variant detected in the PCSK9 gene. No 
variants were identified in the LDLRAP1 gene. Table 8 summarises the details of 
pathogenic FH variants identified in the samples through BaseSpace. 
Table 7 Pathogenic FH variants identified using BaseSpace. 
UHS BaseSpace LDLR APOB PCSK9 APOE LDLRAP1 
31 Samples 
(Source unknown) 
17 (8 has conflictions in 
pathogenicity). 15 0 7 0 
FH20 (27 Samples) 
5 (3 has conflictions in 
pathogenicity). 0 0 3 0 
Bristol (36 
Samples) 
10 (4 has conflictions in 
pathogenicity). 3 1 4 0 
Variant rs2228671 in the LDLR gene had conflicting reports of pathogenicity in the 
literature. Out of the 94 samples screened, 15 samples had this variant detected. 
Table 8 Details of pathogenic FH variants identified in the samples through BaseSpace. 
Variants Numbers rs Consequence 
LDLR 11210912 C>T  15 rs2228671 Stop Gained 
LDLR c.662A>G p.(Asp221Gly) 1 rs373822756 Missense Variant 
LDLR c.1238C>T p.(Thr413Met) 1 rs368562025 Missense Variant 
LDLR c.2547+73G>T 1 
  LDLR 11227625 LDLR c.1796T>C 
p.(Leu599Ser) 1 rs879255025 Missense Variant 
LDLR 11224119 Ch19 T>C LDLR p.(Ile451Thr) 1 rs879254874  Missense Variant 
LDLR c.313+1G>A 3  rs112029328 Splice Donor Variant 
LDLR c.680_681delAC p.(Asp227Glyfs*12) 1 rs387906305 Frameshift 
LDLR c.2054C>T p.(Pro685Leu) 1 rs28942084 Missense Variant 
LDLR c.2029T>C p.(Cys677Arg) 1 rs775092314 Missense Variant 
LDLR c.1444G>A p.(Asp482Asn) 1 rs139624145 Missense Variant 
LDLR c.1061A>T p.(Asp354Val) 1 rs755449669 Missense Variant 
LDLR c.1048C>T p.(Arg350Ter) 1 rs769737896 Stop Gained 
LDLR c.301G>A p.(Glu101Lys) 1 rs144172724 Stop Gained 
APOB c.10580G>A p.(Arg3527Gln) 14  rs5742904 Missense Variant 
APOB c.8882A>G p.(Asn2961Ser) 1 rs142756262 Missense Variant 
APOB c.2981C>T p.(Pro994Leu) 1 rs41288783 Missense Variant 
APOB codons 3110-3655: c.10294C>G 
p.(Gln3432Glu) 1 rs1042023 Missense Variant 
APOB c.11833A>G p.(Thr3945Ala) - class 2 1 rs1801698 Missense Variant 
PCSK9 c.385G>A p.(Asp129Asn) 1 rs778738291 Missense Variant 
APOE (45411941 T>C) 14 rs429358 Missense Variant 
Known FH causing variants detected on LDLR, APOB, PCSK9 and APOE genes by 
BaseSpace. Numbers= Number of patients carrying the variant, rs= reference SNP. 
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3.2.3 Variants of unknown significance identified through BaseSpace 
A total of 1,352 variants of unknown significance (VUS) were identified through 
BaseSpace analysis in the 94 samples as shown in Table 9. In the LDLR gene alone, 
there were 394 variants whose pathogenicity or significance was unknown, in APOB there 
were 466 variants, in PCSK9 there were 485 variants and in LDLRAP1 there were 7 
variants of unknown significance. 
Table 9 Variants of unknown significance. 
UHS BaseSpace 
LDLR 
VUS 
APOB 
VUS 
PCSK9 
VUS 
LDLRAP1 
VUS 
31 Samples (Source 
unknown) 151 203 177 5 
FH20 (27 Samples) 122 115 159 0 
Bristol (36 Samples) 121 148 149 2 
BaseSpace analysis on 94 samples identified a large number of variants across LDLR, 
APOB, PCSK9 and LDLRAP1 whose significance was not known on the dbSNP short 
genetic variation database. 
UHS BaseSpace findings have identified variants in LDLR, APOB and PCKS9 genes 
similar to findings of the Latvian study group (Radovica-Spalvina et al., 2015). Based on 
the evidence from the literature, the Latvian study group had categorised these variants 
into various categories from 1 to 6. Table 10, below summarises some of the variants 
identified in our study similar to the Latvian study. Most of the PCSK9 variants shown in 
the table below from our study have also been previously reported by the Humphries 
study group through Single Strand Confirmation Polymorphism (SSCP) analysis (S E 
Humphries et al., 2006). By identifying some of the common variants, this study has also 
shown that our NGS approach has higher sensitivity and specificity rate. 
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Table 10 Summary of some of the variants identified through BaseSpace similar to the Latvian study group. 
CAT Gene rs code Patient 
no.s 
Variant Description with references 
3 APOB rs1801696 14 p.(Glu2566Lys) Hypertriglyceridemia (Johansen et al., 2010) 
4 APOB rs142151703 2 c.*179G>A No information 
4 APOB rs1801695 4 p.(Ala4481Thr) Associated with HDL (Edmondson et al., 2011), risk of dementia 
(Reynolds et al., 2010), seen in individuals with low TG levels 
(Neale et al., 2011). 
4 APOB rs1042034 66 p.(Ser4338Asn) Common variant (Radovica-Spalvina et al., 2015), benign 
(Mäkelä et al., 2012) 
4 APOB rs1801702 1 p.(Arg4270Thr) Associated with TC and LDL-C(Liao et al., 2008) 
4 APOB rs1042031 36 p.(Glu4181Lys) Common variant (Radovica-Spalvina et al., 2015), benign 
(Mäkelä et al., 2012), influences BMI (Bentzen, Jorgensen, & 
Fenger, 2002) 
4 APOB rs1801701 18 p.(Arg3638Gin) Common variant (Radovica-Spalvina et al., 2015), associated 
With LDL-C (Benn et al., 2008), influences BMI (Bentzen et al., 
2002) 
4 APOB rs533617 7 p.(His1923Arg) Probably damaging to APOB (Mäkelä et al., 2012), seen in 
individuals with low TG (Neale et al., 2011) 
4 APOB rs679899 67 p.(Ala618Val) Probably damaging to APOB (Mäkelä et al., 2012), associated 
with kidney disease (Yoshida et al., 2009), common variant 
(Radovica-Spalvina et al., 2015).  
4 APOB rs72653061 1 c.905-15G>C No information 
4 APOB rs1367117 54 p.(Thr98Ile) Common variant (Calandra et al., 2011), benign (Mäkelä et al., 
2012) 
6 APOB rs676210 30 p.(Pro2739Leu) Hypercholesterolaemia (Benn et al., 2008), common variant 
(Radovica-Spalvina et al., 2015) 
6 APOB rs12691202 5 p.(Val730Ile) As a compound heterozygote with Arg490Trp influences severity 
of hypobetalipoproteinaemia (Lam et al., 2012) 
4 LDLR rs2738442 58 c.1060+7T>C No association with FH (Al-Khateeb et al., 2011) 
4 LDLR rs12710260 37 c.1060+10G>C Found in Greek FH patients (Dedoussis et al., 2004), common 
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variant (Radovica-Spalvina et al., 2015) 
4 LDLR rs11669576 7 p.(Ala391Thr) Associated with increased risk of stroke (Frikke-Schmidt, 
Nordestgaard, Schnohr, & Tybjaerg-Hansen, 2004), found in FH 
patients (Salazar et al., 2002).  
4 LDLR rs14158 43 c.*52G>A Probably benign (Amsellem et al., 2002), common variant 
(Radovica-Spalvina et al., 2015) 
4 LDLR rs17249029 1 c.*338G>A No information 
4 PCSK9 rs45448095 21 c.-64C>T Found in hypercholesteraemic individuals (Leren, 2004), 
common variant (Radovica-Spalvina et al., 2015) 
4 PCSK9 rs2483205 59 c.658-7C>T Found in FH individuals (Tosi et al., 2007), common variant 
(Radovica-Spalvina et al., 2015) 
4 PCSK9 rs2495477 36 c.799+3A>G Found in FH individuals (Leren, 2004), common variant 
(Radovica-Spalvina et al., 2015) 
4 PCSK9 rs562556 55 p.(Val474Ile) Found in both low and high LDL-C groups (Miyake et al., 2008), 
common variant (Leren, 2004)(Al-Waili et al., 2013)(Scartezini et 
al., 2007) 
4 PCSK9 rs505151 57 p.(Gly670Glu) Associated with severity of atherosclerosis (S. N. Chen et al., 
2005), found in hypercholesterolemic individuals (Leren, 2004), 
common polymorphism (Leren, 2004), common variant 
(Radovica-Spalvina et al., 2015) 
4 PCSK9 rs28362287 1 c.*75C>T No information 
4 PCSK9 rs11800231 8 c.524-11G>A Found in FH (Leren, 2004)(S E Humphries et al., 2006) and 
healthy individuals (Radovica-Spalvina et al., 2015) 
4 PCSK9 rs11800243 8 c.657+9G>A Found in FH (Leren, 2004)(S E Humphries et al., 2006) and 
healthy individuals (Radovica-Spalvina et al., 2015) 
UHS BaseSpace variants on LDLR, APOB and PCSK9 genes similar to the Latvian study group. CAT= Designated category of variant by 
Latvian study group. 3= other rare, non-synonymous and potential splice site variants, 4= other rare, synonymous variants and common 
variants, 6= variants with opposite effect. TG= Triglycerides, LDL-C= Low Density Lipoprotein- Cholesterol. 
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3.2.4 Combination of variants in different FH causing genes 
A total of 17 patients had two or more variants identified in the same gene or in a different 
candidate gene known to cause FH. Out of the 17, 10 patients had variants in LDLR and 
APOB genes, 4 patients had variants in LDLR and APOE genes and 3 patients had 
variants in APOB and APOE genes as shown in Table 11. There were 2 patients from the 
Bristol sample group who had 2 variants in the LDLR gene along with a variant in the 
APOB gene. Furthermore, 1 patient from the unknown source group had 2 variants 
identified in the APOB gene along with a variant in the APOE gene. 
Table 11 Combination of variants in the FH causing genes. 
UHS BaseSpace 
LDLR + 
APOB 
LDLR + 
APOE 
APOB + 
APOE 
31 Samples 
(Source unknown) 8 4 2 
FH20 (27 Samples) 0 0 0 
Bristol (36 
Samples) 2 0 1 
Combinations of variants were identified by the BaseSpace.  4 patients had 2 variants in the 
LDLR gene and 2 patients had 2 variants in the APOB gene. 
 
3.3 Comparison of UHS BaseSpace findings with the reference lab 
findings 
As mentioned earlier, there were three patterns of sample sources identified in the 
samples which were analysed for FH variants. There were a total of 31 samples whose 
source or method of analysis was not known. 27 samples were analysed by the FH20 chip 
method and 36 samples were analysed by the Bristol Panel. 
3.3.1 31 samples (source or method of analysis unknown) 
Out of the 31 samples, the reference lab findings showed only 24 samples to have FH 
variants and 7 patients had no FH variants detected. In contrast, our findings showed 28 
patients had FH variants and only 3 had no FH variants detected. On analysing the 
spectrum of FH variants, the reference lab detected 10 FH variants in LDLR gene and 14 
FH variants in APOB gene, where as our BaseSpace detected 17 FH variants in the LDLR 
gene and 18 patients with FH variants in the APOB gene and 7 FH variants in the APOE 
gene. In addition there were 151 FH variants in LDLR gene, 203 FH variants in APOB 
gene, 177 FH variants in the PCSK9 gene and 5 FH variants in the LDLRAP1 whose 
pathogenicity was not known, as shown in Table 12. 
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Table 12 Comparison of findings in 31 samples whose source was unknown. 
Samples Positive Negative LDLR APOB APOE 
LDLR 
VUS 
APOB 
VUS 
PCSK9 
VUS 
LDLRAP1 
VUS 
31 Samples 
(Source 
unknown) 24 7 10 14 
     UHS 28 3 17 18 7 151 203 177 5 
UHS BaseSpace analysis was able to identify more FH variants in patients when compared 
to the reference lab. There were also variants in FH genes whose pathogenicity or 
significance was not known. 
3.3.2 FH 20 samples 
The reference lab detected no FH variants in the 27 samples which were analysed by the 
FH20 chip. Our BaseSpace analysis detected 8 patients with known FH variants; no 
known FH variants were detected in 19 patients. There were 5 patients known to have 
known FH causing variants in the LDLR gene and 3 patients had FH causing variants 
detected in the APOE gene. In addition there were 122 variants detected in the LDLR 
gene, 115 variants in the APOB gene and 159 variants in the PCSK9 gene whose 
pathogenicity was not known as shown in Table 13. 
Table 13 Comparison of FH variants in 27 samples of FH20. 
Samples Positive Negative LDLR APOB APOE 
LDLR 
VUS 
APOB 
VUS 
PCSK9 
VUS 
LDLRAP1 
VUS 
FH 20 0 27 
       UHS 8 19 5 
 
3 122 115 159 
 UHS BaseSpace analysis was able to identify FH variants in 8 patients out of the 27 samples 
in the FH20 group. 
3.3.3 Bristol 36 samples 
The last group of 36 samples were analysed by the Bristol panel. The reference lab 
detected FH causing variants in 12 patients and the remaining 24 patients had no FH 
causing variants detected in their samples. In total, there were 8 patients who had FH 
causing variants in the LDLR gene, 3 patients had FH causing variants in the APOB gene 
and 1 patient had FH causing variant detected in the PCSK9 gene. In contrast, our 
BaseSpace findings detected FH causing variants in 22 patients and in the remaining 14 
patients there were no known FH causing variants detected. Overall, a total of 10 known 
FH causing variants were detected in the LDLR gene, 9 known FH causing variants were 
detected in the APOB gene, 4 known FH causing variants in the APOE gene and 1 known 
FH causing variant in the PCSK9 gene. In addition, there were 121 variants in the LDLR 
gene, 148 variants in the APOB gene, 149 variants in the PCSK9 gene and 2 variants in 
the LDLRAP1 whose pathogenicity was not known, as shown in Table 14. 
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Table 14 Comparison of FH variants in the 36 Bristol panel samples. 
Samples Positive Negative LDLR APOB APOE PCSK9 
LDLR 
VUS 
APOB 
VUS 
PCSK9 
VUS 
LDLRAP1 
VUS 
Bristol(36 
Samples) 12 24 8 3 
 
1 
    UHS 22 14 10 9 4 1 121 148 149 2 
UHS BaseSpace analysis was able to identify more FH variants in the Bristol sample group. 
There were variants identified in the FH causing genes whose pathogenicity or significance 
was not known. 
3.4 Investigation of non-concordant results 
On completion of the bioinformatics analysis on all the 94 samples, the UHS BaseSpace 
findings were compared with the reference lab findings. Out of the 94 samples, there were 
11 samples where variants could not be identified by UHS BaseSpace and were not in 
concordance with the reference lab findings. All 11 samples had variants identified in their 
LDLR gene by the reference lab as shown in Table 15. 
Table 15 Samples which were not in concordance with the reference lab findings. 
Sample number Variant rs 
1107996864 LDLR c.662A>G rs373822756 
1107996791 LDLR c.1238C>T rs368562025 
1107996839 LDLR c.2042G>C rs201637900 
1107996837 LDLR c.2547+73G>T  
1107996821 LDLR c.661G>A rs875989906 
1107996798 LDLR c.681C>G rs121908028 
1107996822 LDLR c.662A>G rs373822756 
1107996786 LDLR c.681C>G rs121908028 
1107996029 LDLR c.2029T>C rs775092314 
1107996006 LDLR c.1061A>T rs755449669 
1107996070 LDLR c.1048C>T rs769737896 
List of 11 samples which were not in concordance with the reference lab findings.               
All 11 samples had variant in the LDLR gene. 
The BaseSpace analysis results on these 11 samples were individually looked into. Out of 
the 11 samples, BaseSpace was able to identify the nucleotide change in the sequences 
in 6 samples but were not able to call them with a dbSNP number. These 6 samples 
showed considerable total depth i.e. number of reads aligned at the respective position 
and considerable alt depth i.e. number of reads containing the variant allele as shown in 
Table 16. The exact position of the variants on the BaseSpace within the reference 
chromosome were noted and searched on the NCBI LDLR gene using the genomic 
sequence Chromosome 19 Reference GRCh37.p13 primary assembly. All the 6 samples 
showed variants in the LDLR gene and were in concordance with the reference lab 
results. 
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Table 16 Identification of variants in BaseSpace by manual analysis. 
Samples rs Location Variant Total depth Alt depth 
1107996864 rs373822756 
11216244 
A>G 
LDLR c.662A>G 
p.(Asp221Gly) 
412 159 
1107996791 rs368562025 
11224005 
C>T 
LDLR 
c.1238C>T 
p.(Thr413Met) 
307 166 
1107996837 
 
11240419 
G>T 
LDLR 
c.2547+73G>T 
Intron 
449 222 
1107996029 rs775092314 
11231087 
T>C 
LDLR 
c.2029T>C 
p.(Cys677Arg) 
195 85 
1107996006 rs755449669 
11222190 
A>T 
LDLR 
c.1061A>T 
p.(Asp354Val) 
197 101 
1107996070 rs769737896 
11221435 
C>T 
LDLR 
c.1048C>T 
p.(Arg350Ter) 
431 220 
LDLR variants identified on BaseSpace which did not have a dbSNP identifier. Total depth= 
Number of reads aligned at the respective position, Alt depth= Number of reads containing 
the variant allele. 
The remaining 5 (1107996821, 1107996798, 1107996822, 1107996786 and 1107996839) 
samples did not show any variants in the BaseSpace analysis. These 5 samples were run 
on the Galaxy through a pipeline specially constructed and designed for this FH-NGS 
study as shown in Figure 35 in the methods section. Galaxy was also not able to identify 
any variants in these 5 samples. Since there were no variants identified on the 5 samples 
both on BaseSpace and Galaxy, the .vcf files of these 5 samples were loaded on 
Integrated Genome Viewer (IGV) to see if there were any coverage issues. On loading the 
.vcf files on the IGV it was found that there was no coverage in the respective regions and 
hence the variants could not be detected as shown in Figures 39, 40 and 41. 
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Figure 39 IGV screen shot showing no coverage in some of the exons and poor coverage in few exons in the LDLR gene. Faint grey colour indicates 
no coverage and dark grey colour indicates good coverage of the exons. 
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Figure 40 IGV screen shot on 4 samples showing no coverage around 11216263bp, 11216243bp and 11216244bp regions of the LDLR gene. 4 
samples 1107996821, 1107996798, 1107996822 and 1107996786 on the IGV showing no coverage on the exon 4 of the LDLR gene.  
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Figure 41 IGV screen shot on sample 1107996839 showing no coverage at location 11231100bp in the exon 14 of the LDLR gene. 
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3.5 Sanger sequencing 
Sanger sequencing was performed as a gap-filling analysis for this FH-NGS study since 
no variants could be identified both by BaseSpace and Galaxy due to coverage issues. 
Reference lab findings indicated the presence of FH variants in the LDLR gene on exons 
4 and 14. Hence, targeted Sanger sequencing was performed to detect the variants in the 
LDLR gene on exons 4 and 14. The sequences of five samples were loaded on the 
Mutation Surveyor® DNA Variant Analysis software for identification of the variants in the 
LDLR gene. Sanger sequencing identified variants in the LDLR gene on all 5 sample 
which were in concordance with the reference lab findings (Table 17). 
Table 17 Variants identified in the LDLR gene by Sanger sequencing. 
Samples rs Variant 
1107996821 rs875989906  LDLR c.661G>A p.(Asp221Asn) 
1107996798 rs121908028  LDLR c.681C>G p.(Asp227Glu) 
1107996822 rs373822756 LDLR c.662A>G p.(Asp221Gly) 
1107996786 rs121908028    LDLR c.681C>G p.(Asp227Glu) 
1107996839 rs201637900 LDLR c.2042G>C p.(Cys681Ser) 
LDLR variants were identified in 5 samples by Sanger sequencing. These variants           
were not detected by BaseSpace due to the coverage issues.  
Out of the five patients, two patients had LDLR c.681C>G p.(Asp227Glu) variant, one 
patient had LDLR c.661G>A p.(Asp221Asn) variant, one patient had LDLR c.662A>G 
p.(Asp221Gly) variant and one patient had LDLR c.2042G>C p.(Cys681Ser) variant as 
shown in Figure 42. 
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Figure 42 Sanger sequencing electropherogram showing LDLR variants. Mutation Surveyor® software was used to analyse and discover the LDLR 
variants from the Sanger sequencing. 
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4. Discussion 
FH is an autosomal dominant inherited disorder characterised by raised blood plasma 
cholesterol levels. Increased plasma cholesterol can lead to its deposition in the 
peripheral tissues, leading to xanthomas, and deposition in the arterial wall can lead to 
CHD. It is estimated that there are 10 million subjects with FH worldwide. It is evident from 
the literature, that early diagnosis and treatment can significantly reduce the mortality rate 
and can have a significant impact on the life expectancy in FH patients (Finnie et al., 
2012) (Joseph L Goldstein, 2001).  
The identification, early treatment and management of affected individuals still remains a 
major challenge, and underdiagnosis of FH is a huge worldwide problem (Neil et al., 
2000). Diagnosis has often been through physical examination for xanthomas, complete 
family history for CHD and a laboratory blood test for measuring blood plasma cholesterol 
levels. It is evident from the literature that almost 50% of patients do not display any 
physical signs (Colin A. Graham et al., 1999) and there is often no evidence of CHD in 
heterozygous FH patients (Bhagavan & Jackson, 2002) and in some, plasma cholesterol 
levels have been to be found around normal levels. Therefore, diagnosis based on just 
physical symptoms and family history has proven to be insufficient and further genetic 
testing is mandatory for FH diagnosis. Recent findings also suggest the prevalence of FH 
has been higher than previously thought and the proportion of patients known to have FH 
remains low. Therefore, genetic testing is pivotal to timely diagnosis and management of 
these patients to prevent early mortality and morbidity. At present a combination of 
genetic tests are being employed to screen and diagnose FH. This process is labour 
intensive, time consuming and involves more staffing, the throughput is limited and the 
associated costs are high. The sensitivity of these combined different approaches also is 
found to be variable (Maglio et al., 2014). 
Although genetic testing is the definitive way of diagnosing FH and has been widely 
accepted as a gold standard, it is very important to acknowledge that LDL cholesterol is 
the main driver for CVD risk rather than the presence of a molecular defect. In addition, 
LDL cholesterol measurements also aid in tailoring therapies and management strategies. 
However, genetic testing plays an important role in identifying variants which leads to 
raised blood plasma cholesterol levels. Moreover, it is evident from the literature and also 
from our study findings that FH phenotype could be due the presence of multiple variants 
in a number of genes suggesting a polygenic cause to be the reason for raised blood 
plasma cholesterol levels similar to the monogenic forms (Talmud et al., 2013). Hence it is 
important to acknowledge biochemical diagnosis coupled with genetic diagnosis is the 
most effective way to diagnose and screen patients suspected to have FH. 
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In recent years, huge advances have been made in the area of genetic testing technology, 
and a major aim is to translate these into routine diagnostics in order to improve our 
current clinical diagnostic service. The ability of NGS platforms to process a large volume 
of data in a short period of time makes NGS technology a powerful tool for screening and 
diagnosing diseases on a large scale. In addition, the ability of NGS to multiplex several 
samples as well as its ability to analyse multiple genes in a single run offers significant 
cost reduction over single gene testing which makes it a powerful diagnostic platform of 
choice to be used by the NHS of the future. With great developments in sequencing 
technologies, single nucleotide polymorphism (SNP) has become the marker of choice in 
the wide range of genetic analysis. SNP refers to a polymorphism i.e. change in a 
nucleotide base at a particular position in comparison to the reference sequence. 
Recently, researchers have shown that copy number variants in the LDLR gene can be 
successfully identified by mining the NGS data through depth of coverage analysis 
(Iacocca et al., 2017). They have successfully demonstrated and concluded that multiplex 
ligation-dependant probe amplification (MLPA) can be removed from the routine 
diagnostic screening process of FH and thereby significantly reducing the associated 
costs, resources and analysis time (Iacocca et al., 2017).  
This study has demonstrated that NGS can be used to effectively screen and diagnose 
FH without using much of the traditional genetic tests. In addition, this study has also 
demonstrated that a targeted NGS approach is very effective in the screening and 
diagnosis of FH, since it greatly reduces the genetic screening range in comparison to 
whole exome sequencing (WES). It is also cost effective when compared to WES and 
also the data analysis can be effectively performed with greater efficiency. Furthermore, 
development of NGS for routine diagnostics in the NHS can aid an efficient, rapid and 
affordable mutation analysis methodology in other areas beyond FH.  
A total of 94 samples from patients known and suspected to suffer from FH were 
screened using targeted next generation sequencing on LDLR, APOB, PCSK9, LDLRAP1 
and APOE genes using the Illumina MiSeq® system. Out of the 94 samples analysed, 
BaseSpace analysis detected 62 patients with FH variants whilst 32 patients had no FH 
variants detected in their samples. A total of 32 FH variants were detected in the LDLR 
gene of which 17 patients had known pathogenic FH variants and 15 patients had variants 
whose pathogenicity was unknown or had conflicting reports of their pathogenicity in the 
literature. In addition, 18 patients had FH variants detected in APOB gene, 14 patients 
had FH variants detected in their APOE gene and 1 patient had a known FH variant 
detected in the PCSK9 gene. No variants were identified in the LDLRAP1 gene. Several 
variants detected in this cohort as shown in Table 8 of the results section were all well-
96 
 
known variants previously described in the literature. In addition, a total of 1,352 variants 
of unknown significance (VUS) were identified through BaseSpace analysis in the 94 
samples. In the LDLR gene alone, there were 394 variants whose pathogenicity or 
significance was unknown, in APOB there were 466 variants, in PCSK9 there were 485 
variants and in LDLRAP1 there were 7 variants of unknown significance. Some of these 
variants shown in Table 10 of the results section were previously reported by the Latvian 
study group. 
The UHS BaseSpace findings were compared with the reference lab findings. Our NGS 
approach was able to identify FH variants in the 26 patients out of 58, in whom no FH 
variants were previously detected by the reference lab. In 6 samples, BaseSpace was 
able to identify FH variants, but was not able to designate them as pathogenic. The exact 
positions of these variants on the BaseSpace were located in the NCBI LDLR genomic 
sequence using the Chromosome 19 Reference GRCh37.p13 primary assembly. All 6 
samples showed FH variants in the LDLR gene and were in concordance with the 
reference lab findings. However, there were 5 samples where BaseSpace was not able to 
identify FH variants in the LDLR gene. There could be number of reasons for not being 
able to identify the FH variants in those 5 samples. On review of the literature these could 
be drawn into 6 areas: (i) sample quality, (ii) edge effect, (iii) technical issues, (iv) 
amplicon issues, (v) panel design and (vi) analytical and clinical validity of the software. 
4.1 Investigation of non-concordant results 
 
4.1.1 Sample quality 
High quality, intact pure DNA is essential for accurate and reliable NGS. For successful 
high quality library preparation it is essential to have a high quality genomic DNA as 
source material. As evident from the literature, the DNA should be freshly purified, free 
from DNases and have an OD260/280 ratio between 1.8 to 2.0 and an OD260/230 ratio of 2.0 
to 2.2 (Endrullat, Glökler, Franke, & Frohme, 2016) on the NanoDrop®. The ratio of 
absorbance at 260 and 280 nm is used to assess the purity of nucleic acid and a ratio of 
~1.8 is generally accepted as ‘pure’ for DNA (Wilfinger, Mackey, & Chomczynski, 1997), 
with a lower ratio indicating protein contamination. OD260/230 is generally used as a 
secondary measure of nucleic acid purity and a ratio below 2.0 indicates the presence of 
contaminants (Wilfinger et al., 1997) such as salts and solvents (phenol). In the 5 
discordant samples, 4 samples had an OD260/280 ratio above 1.8 except one sample 
1107996798 as shown in the Table below which had a ratio of ~1.73. Three out of the 5 
discordant samples had an OD260/230 less than ~2.0 as shown in the Table 18 which 
indicated the presence of contaminants. The genomic DNA concentrations were also low 
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in two of the five samples by NanoDrop®. Sample 1107996798 had a DNA concentration 
of 50.7ng/µl and sample 1107996822 had a DNA concentration of 45.6ng/µl. Qubit® 
findings also illustrated the differences in the genomic DNA concentration in comparison 
to the NanoDrop® findings as shown in Table 18. It is also important to note that 3 of the 5 
samples (1107996798, 1107996822 and 1107996786) had genomic DNA concentrations 
below the minimum input recommendations (50ng) when measured by Qubit®. Therefore, 
with the Qubit® and NanoDrop® findings and through the review of literature, it can be 
concluded that a combination of contaminants and low DNA concentration in the samples 
could have been one of the reasons for non-concordant results in comparison to the 
reference lab findings. 
Table 18 NanoDrop® and Qubit® findings on the 5 discordant samples. 
Sample 1107996839 1107996821 1107996798 1107996822 1107996786 
OD260/280 1.89 1.93 1.73 2.4 1.98 
OD260/230 2.37 2.02 1.37 1.99 1.9 
Nano drop® 
(ng/µl) 
303.1 164.8 50.7 45.6 109.6 
Qubit® (ng/µl) 129 60 11.9 12.4 38 
OD260/280 = Ratio of absorbance used to assess the purity of DNA and RNA, OD260/230 = Ratio of 
absorbance used to assess the nucleic acid purity. ng= nanogram. 
4.1.2 Edge effects 
Edge effect is a phenomenon which mainly affects the peripheral wells of the plate during 
the incubation phase which can alter the volume in the well, its concentration and the 
evaporation rates. Edge effect is a major yet understated problem, which contributes to 
deterioration of assays in experiments (Lundholt, Scudder, & Pagliaro, 2003). The causes 
of edge effects are complex and evaporation during the incubation phase has been one of 
the major problems. There are several reports on edge effect in microplate-based 
experiments which are due to differences in thermal gradients (Burt, Carter, & Kricka, 
1979) (Oliver, Sanders, Douglas Hogg, & Woods Hellman, 1981) and due to differential 
adsorption (Kricka et al., 1980) characteristics across the plate. Thermal gradients are 
greatest in the edge wells of the plates (Lundholt et al., 2003). It has been a common 
practice in many labs to avoid the use of peripheral wells on the plate to avoid the edge 
effects. In our FH-NGS study, the locations of the 5 discordant samples on the 96 well 
plate were identified so as to rule out the edge effect. The five samples, 1107996839, 
1107996821, 1107996798, 1107996822 and 1107996786 were located in positions F02, 
E05, C06, E06 and B07. The exact locations of the 5 samples on the 96 well plate 
revealed that the edge effect could be excluded as reason for not being able to detect the 
variants in the LDLR gene. 
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4.1.3 Technical issues 
Batch analysis issues or batch effects are a common and a very powerful source of 
variation in the high throughput experiments (Leek et al., 2010). In the majority of the 
cases, batch effect leads to increased variability in the outcome of the experiments and 
also decreases the ability to detect the significant biological signals (Leek et al., 2010). 
However, if properly dealt with, the problems caused by batch effects can be prevented. 
Some of the common reasons for batch effects are technical, such as variations in 
pipetting techniques, laboratory conditions, reagent lots, analysing personnel, laboratory 
temperature, storage of reagents, equipment issues and training (Head et al., 2014). It is 
evident from the published studies that batch effects and other technical artefacts are 
critical issues to be addressed as the technical variability can be more damaging than the 
biological variability (Leek et al., 2010). Nevertheless, as all the samples were processed 
using the same lot of reagents and in the same, temperature-controlled, laboratory 
environment, at least these factors can likely be excluded. Hence, I could narrow the 
reason for non-concordant results to technical issues; I then started investigating further 
by looking into the way the samples were processed by plotting the data on a 
spreadsheet. 
In our FH-NGS study, 94 samples were processed in 3 batches of 24, 36 and 34 samples. 
On plotting the information on a spreadsheet (Excel), it was found that 4 of the 5 
discordant samples were in batch two. The coverage file of the FH-NGS run from the 
MiSeq analyser was also uploaded on a spreadsheet to investigate batch issues and 
coverage issues as shown in Appendix 5. It was observed from the spreadsheet data that 
there were batch testing issues, as a few samples from the batch 2 had poor coverage 
across few amplicons. On reviewing the literature, I speculated and looked into batch 
testing issues arising due to improper PCR amplification (Akbari, Hansen, Halgunset, 
Skorpen, & Krokan, 2005) and improper mixing of reagents (McIntyre et al., 2011). PCR 
amplification issues could be due to a number of reasons; using inappropriate number of 
cycles in the PCR, inappropriate temperature, using incorrect PCR plates in the thermal 
cycler i.e. using a round bottom PCR plate in a thermal cycler which accommodates only 
flat bottom PCR plates. Nevertheless, all three batches of samples were analysed using 
the same PCR programme, same thermal cycler and similar PCR plates and hence these 
factors can likely be excluded. This then leaves the option of improper mixing which could 
be the reason for the batch testing issues. It is generally known that pipetting skills are 
very significant and play an important role in any assay which involves steps of manual 
mixing using pipettes. Throughout the experiment, I used single channelled and multi-
channelled pipettes. Using multi-channelled pipette requires special practice and skills 
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and even an experienced user can sometimes find it difficult to use. Usage of multi-
channelled pipette by inexperienced users can lead to pipetting errors and could lead to 
assay failures. It could be speculated that pipetting and mixing reagents using multi-
channel pipettes could be the reason for issues in batch 2 samples.  
Furthermore, the .vcf files of the 5 discordant samples were loaded on the IGV as shown 
in Figure 38 and Figure 39 of the results section which showed no coverage in the LDLR 
region where the variants were located. On mining the data on the spreadsheet, it was 
evident that there were a few low performing amplicons which resulted in low coverage or 
no coverage at all. With the available evidence on the spreadsheet and through IGV data, 
it can be concluded that a combination of batch issues and some low performing 
amplicons resulted in coverage issues which led to the non-concordant results in the five 
samples. 
4.1.4 Amplicon issues 
PCR amplicon-based sequencing is widely used as a targeted approach for both DNA and 
RNA workflows (Peng, Vijaya Satya, Lewis, Randad, & Wang, 2015). However, one of the 
limitations with this approach is coverage issues due to failed amplicons or low 
performance amplicons (Froyen et al., 2016) and also incomplete coverage arising from 
the limits of multiplexing (Radovica-Spalvina et al., 2015). Inadequate coverage can result 
in the failure of detection of variants leading to false-negative results for heterozygotes 
(Wheeler et al., 2008) (Bentley et al., 2008). Identification of these low performing or failed 
amplicons in a panel is very important for laboratories using them for routine diagnosis 
(Yan et al., 2016). In addition, it is evident from the literature that massively parallel 
sequencing approaches do not provide adequate coverage of all regions, particularly the 
GC–rich regions in the hybridisation based capture methods and is not able to sequence 
through homopolymer regions in pyrosequencing and semi-conductor based methods 
(Faiz et al., 2014). In addition, studies have shown that in most of the NGS experiments, 
low performing amplicons result in coverage issues (Samorodnitsky et al., 2015). In our 
FH-NGS study, when the coverage file from MiSeq analyser was exported to an Excel 
spreadsheet, it became evident that there were a few low performing amplicons and these 
amplicons showed no coverage across all the 94 samples. I also loaded the .vcf files of 
the 5 non-concordant samples on the IGV and it was clearly evident that there were no 
coverage and hence we were not able to detect the variants in those 5 samples. However, 
on performing gap filling analysis with Sanger sequencing on those 5 samples we were 
able to detect the variants and show that they were in concordance with the reference lab 
results. Therefore, it can be confirmed and concluded that coverage issues and a few low 
performing amplicons were the reason for non-concordance in the 5 samples. 
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4.1.5 Panel design 
One of the limitations in our study is the panels were in silico designed and not wet lab 
validated. This could be the reason for some of the low performing amplicons, as they 
were not subjected to systematic optimisation and performance testing by the provider. 
With NGS creating major impacts on our routine molecular diagnostic services, many 
laboratories have started tailoring their custom panels through diagnostic companies who 
offer the flexibility to design the panels of choice as per the requirements. Some 
laboratories include only core genes based on the evidence in the literature and some 
also include genes involved in the cholesterol pathways for which evidence is still 
emerging. However, these panels need to be wet lab validated with considerable 
optimisation (Jennings et al., 2017) before they can be used in routine diagnostics. 
Optimisation and familiarisation is a process whereby samples are subjected to NGS test, 
from library preparation to sequencing and variant calling so that it can be systematically 
evaluated (Jennings et al., 2017). However, at present there are now wet lab validated, off 
the shelf bespoke panels which can be used in routine FH screening services after 
extensive verification but without the requirement for any in house optimisation and 
validation. These off the shelf bespoke panels were not available at the time of our study. 
At present, there are a handful of diagnostic companies which provide off the shelf 
bespoke panels which have been optimised and wet lab validated which are capable of 
detecting SNV’s and copy number variants (CNV’s) as shown in Table 19. In our opinion, 
these off the shelf bespoke panels could be the future for targeted sequencing which 
offers options for mix and match and also allows the labs to customise the required core 
genes and hotspots. 
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Table 19 Off the shelf bespoke FH panels. 
Provider Name Genes Method Detects Weblink 
Oxford Gene 
Technology 
SureSeq myPanel™ NGS 
custom FH panel 
LDLR, PCSK9, APOB, LDLRAP1, 
APOE, LIPA, STAP1 and Hotspots 
NGS SNV, CNV https://www.ogt.com/products/1350_sureseq_m
ypanel_ngs_custom_fh_panel 
Progenika 
Biopharma 
SEQPRO LIPO IS LDLR, APOB, PCSK9, APOE, STAP1 
(ADH) and LDLRAP1 
NGS SNV http://www.progenika.com/other_regions/index.
php?option=com_content&task=view&id=325&It
emid=415 
GB 
HealthWatch 
Genetic tests 
Familial 
Hypercholesterolemia 
Panel  
ABCA1, APOB, LDLR, LDLRAP1, 
PCSK9, STAP1, APOA2, EPHX2, 
ITIH4 
NGS SNV, CNV https://www.gbhealthwatch.com/gbinsight/gb-
panels-
info.php?catalog=GBDNA2031&target=gene 
Ambry 
Genetics 
FHNext APOB, LDLR, PCSK9, LDLRAP1 NGS SNV, CNV http://www.ambrygen.com/clinician/genetic-
testing/13/cardiology/fhnext-1 
CGC genetics Hypercholesterolemia, 
familial (NGS panel for 15 
genes) 
ABCA1, ABCG5, ABCG8, APOA2, 
APOB, APTX, EPHX2, GHR, ITIH4, 
LDLR, LDLRAP1, LIPA, LRP6, PCSK9, 
PPP1R17 
NGS SNV http://www.cgcgenetics.com/en/by-
specialty/3864 
Blueprint 
Genetics 
Hyperlipidemia Core 
Panel 
APOB, LDLR, LDLRAP1, PCSK9 NGS SNV, CNV https://blueprintgenetics.com/tests/panels/cardi
ology/hyperlipidemia-core-panel/ 
Phosphorus 
diagnostics 
Familial 
Hypercholesterolemia 
Panel 
APOB, LDLR, LDLRAP1, PCSK9 NGS SNV, CNV http://phosphorus.com/diagnostics/familial-
hypercholesterolemia-panel/ 
Fulgent Familial 
Hypercholesterolemia 
NGS Panel 
APOB, LDLR, LDLRAP1, PCSK9, 
SLCO1B1 
NGS SNV  https://www.fulgentgenetics.com/familial-
hypercholesterolemia 
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The joint consensus recommendation of the Association for Molecular Pathology and 
College of American Pathologists addresses the significance of NGS test development, 
optimisation and validation, including recommendations on panel content selection and 
rationale for optimisation and familiarisation phase conducted before test validation 
(Jennings et al., 2017). In our study, the panel design and its in silico validation by the 
provider was a clear limitation. Through this study we were able to demonstrate and show 
problems of in silico designed panels and its implications on clinical validity. In our 
opinion, these off the shelf bespoke wet lab validated panels can be time saving and more 
cost effective to cater for the needs of the NHS laboratories without the need for further 
optimisation and validation. 
4.1.6 Analytical validity and clinical validity of the analytical software 
The Centres for Disease Control and prevention (CDC) office of Public Health Genomics 
has developed a framework to evaluate the validity and utility of the emerging genetic 
tests based on several factors as shown in Figure 43.  Considering these variables in the 
context of bioinformatics is essential for successful implementation of NGS as well as to 
provide a routine NGS diagnostic service in the NHS. In this context, analytical validity can 
be defined as the ability of the test to detect the genotype of interest and clinical validity 
can be defined as the availability of the scientific evidence to categorise the variant as 
pathogenic or non-pathogenic i.e. the association of the variant with the disease. 
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Figure 43 ACCE Model Process for evaluating genetic tests (Haddow & Palomaki, 2004). 
ACCE takes its name from four of its main criteria- analytical validity, clinical validity, clinical utility 
and associated ethical, legal and social implications. PPV: Positive predictive value, NPP: Negative 
predictive value, QC: Quality control. 
In our FH-NGS study we used BaseSpace®; a cloud-based computing system provided 
by Illumina, Galaxy and wANNOVAR platforms for bioinformatics analysis. The 
bioinformatic analysis on all the 94 samples was performed using Illumina BaseSpace®. 
Galaxy platform and wANNOVAR were also used to perform the bioinformatics analysis 
only on samples which had discordant results in comparison with the reference lab 
findings. Through the study findings I was able to come across one of the limitations of 
Illumina BaseSpace®, whereby the BaseSpace® was able to identify a change in 
nucleotide in the sequences but was unable to identify them as pathogenic variants and 
there were 6 samples in our study with this issue. This suggests that BaseSpace® had 
analytical validity but poor clinical validity, since it was able to identify the nucleotide 
change but was unable to associate the variant with the disease. Through the study 
findings it can also be acknowledged that, at present the clinical utility of the rich 
bioinformatics data from the BaseSpace® is not being exploited to its fullest potential. One 
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way to achieve this would be to perform more studies and in silico analyses to gather 
more evidence on the variants of unknown significance so as to be able to categorise 
them as pathogenic or non-pathogenic. 
Through the investigations, I can conclude that coverage issues due to few low performing 
amplicons were the main reasons for not being able to detect the variants in the 5 
samples which were not in concordance with the reference lab findings. If the panel had 
been subjected to intense wet lab validation by the provider, these low performing 
amplicons could have been identified during the process and could have been optimised 
before it was being sold to the users. Secondly, poor sample quality and batch testing 
issues could have compounded with the coverage issues. 
4.2 Barriers for implementation of an NGS-based FH mutation testing 
strategy in the NHS 
Establishing and implementing a new service in the NHS is very complicated and requires 
rigorous planning. However, in this current era of the genomic revolution, with genomic 
discoveries being made and published almost every week and with the rapid pace of 
developments using NGS technologies, it is necessary for NHS laboratories to embrace 
this technology at the earliest opportunity for the benefit of public healthcare. It is also 
important to acknowledge that there is a need for training and the development of 
healthcare professionals working within the NHS, so that they can gain the ability to 
understand complex genetic and genomic information to potentially adopt the new 
emerging branch of medicine, the so-called “personalised medicine” of modern clinical 
care.  
Although NGS has been the forefront of the genomic technologies, its implementation into 
routine diagnostics in the NHS is slow due to bioinformatic challenges, high costs, 
generation of unprecedented volumes of data which in turn creates challenges and 
opportunities for data management, in its storage, computational resources, infrastructure, 
analysis and interpretation. Hence, for successful implementation in the NHS, it is very 
important to demonstrate the cost effectiveness of these genomic tests in routine 
diagnostics along with their clinical utility and its efficacy in comparison to the existing 
traditional methodologies. 
4.2.1 Bioinformatic analysis 
Bioinformatic analysis is a process through which sequence reads are aligned to a 
reference genome for annotation and variant discovery. Generation of significant clinical 
and diagnostic information from the raw sequencing data through bioinformatics analysis 
is very important for any NGS experiments. However, one of the practical difficulties is the 
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presentation of this complex data to clinicians in a way which could be easily understood 
and used by them to effectively manage and treat their patients.  
At present, there are large numbers of software suites available for bioinformatic data 
analysis. These softwares are either open source or commercially available as supplied 
by the provider. Most of the commercial providers cover the analytical process from read 
alignment to variant annotation whereas in-house pipelines utilise different programmes 
for read alignment, removal of duplicate reads, quality calibration, variant calling and 
annotation (Deans et al., 2015).  
Big data often poses complex bioinformatics challenges and expert bioinformatics 
knowledge is required in the NHS laboratories to analyse and deal with complex 
bioinformatics data. As evident from the house of commons report on genomics and 
genome editing in the NHS, it is important to acknowledge that there are gaps in training 
required for the implementation of genomic services in the NHS (Science and Technology 
Committee. House of Commons., 2018). Hence, in the current climate, it is significant for 
the NHS to invest in more training of existing scientists to study bioinformatics as well as 
to recruit specially trained bioinformaticians in order to embed NGS into our routine 
practice and also for successful implementation of NGS in our routine diagnostic services. 
Hence, recruitment and retention of skilled bioinformatics workforce is essential for the 
successful implementation of NGS in the NHS. 
Use of Artificial Intelligence (AI) in interpreting and analysing complex bioinformatics data 
could be one of the solutions for the NHS of the future. AI can handle and analyse large 
amounts of data faster than humans. Making sense of the enormous amount of data 
generated by the NGS analysers is a huge challenge and this is one of the areas where AI 
excels humans (Loh, 2018). A recent study on genomics has shown that AI platform took 
just 10 mins to analyse a genome of a patient with brain cancer and suggest a treatment 
plan in comparison to human experts who took 160 hours (Wrzeszczynski et al., 2017). It 
is evident from the literature that researchers are currently using machine learning to 
identify patterns in the large volume genetic data sets (Libbrecht & Noble, 2015). These 
patterns are then translated into computer models which may help to predict the 
probability of an individual developing a disease or aid in designing potential therapies.  
Major giants such as Google are already developing computational systems that can 
learn, analyse and interpret genetic variations. Deep Variant an AI tool introduced by 
Google is an analysis pipeline which uses neural networks to call variants from the NGS 
datasets (Anderson, 2018). It is capable of identifying small insertions, deletions and 
single-base-pair mutations in the sequencing data. Integration of AI in genomics will aid in 
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analysis and interpretation of genomic data which is complex even for experts. These AI 
approaches will also aid in quicker identification of diseases as well as design potential 
drug therapies favouring a personalised medicine approach (Loh, 2018). Use of AI in 
analysing and interpreting NGS data will aid the healthcare industry to make big leaps in 
the coming years. However, only time will tell when these AI tools could be available in the 
NHS. 
4.2.2 Big data 
NGS is considered to be a paradigm shift from conventional Sanger sequencing, in the 
scale of the massively parallel sequencing of NGS technology. In the last few years the 
ability of NGS platforms to produce large volumes of data in a short period of time has 
rapidly increased and has outpaced Moore’s Law (Simó, Cifuentes, & García-Cañas, 
2014) (Krampis & Wultsch, 2015). It is known that sequencing a single person’s genome 
will generate 100’s of gigabytes of raw data and further analysis of this genome will 
generate 1 gigabyte of data (Beigh, 2016). NHS laboratories are currently not equipped 
and need to meet these infrastructure and computational challenges before implementing 
any NGS analysis. The time necessary for the analysis of NGS data greatly depends on 
the data volumes, hardware and software packages and computational power which exist 
in the NHS laboratories. With the massive amount of data generated, there will always be 
a trade-off between speed and accuracy of analysis and a balance would be required to 
have an ideal alignment and computational efficiency to effectively analyse the data and 
aid in timely diagnosis. However, majority of the NGS platforms are now integrated with 
bioinformatics applications and tools and the introduction of benchtop analysers with 
much simpler methodologies will aid the scientists to analyse and interpret the large scale 
genomic data much quicker than before and therefore will pave the way for its translation 
into routine diagnostics. 
This complex big data and its analysis obviously poses great bioinformatics challenges 
and opportunities to the laboratories and one of the big challenges for laboratories is 
converting this big data into actionable clinical outcomes and storing them. Hence, it is 
important to acknowledge that significant digital infrastructure is required and huge 
amount of work needs to be done on the digital front in order to provide a routine genomic 
service in the NHS (Science and Technology Committee. House of Commons., 2018). 
Currently NHS England through Global Digital Exemplars (GDE Initiative) is safely 
harnessing the power of technology to integrate and store all patient information digitally, 
so that healthcare providers and patients can have access to all their data and can be 
securely used to improve patient outcomes and the value of services. Through 
digitalisation, clinicians can have access to all healthcare information concerning the 
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patient, to aid in timely diagnosis and management. Already we are witnessing the 
integration of computer systems in pathology and radiology to aid in diagnosis and provide 
answers which are even difficult for experienced pathologists (Granter, Beck, & Papke Jr, 
2017). Artificial Intelligence offers solutions and could be the new weapon in our fight 
against diseases. AI can be used to mine the electronic health care records for patient 
history, digital images, laboratory results and genomic data to aid in precision diagnosis. 
Recent findings have shown the success of AI in accurate identification various medical 
conditions ranging from the identification of cataracts in diabetic patients (Long et al., 
2017), classifying skin cancers in competence with expert dermatologists (Esteva et al., 
2017) and accurate prediction of cardiovascular risk (Weng, Reps, Kai, Garibaldi, & 
Qureshi, 2017). Even the UK government has proposed plans for the NHS to use AI to 
transform the diagnosis of many diseases including cancer and aid in early management 
of these patients (Prime Minister’s office & The Rt Hon Theresa May MP, 2018).  
Efforts should also be taken to streamline the digitalisation and integration of the genomic 
data and should be considered as a part of the general digital reconfiguration in the NHS. 
Systems should be developed to store the genomic data within the patient’s electronic 
record and should be presentable in a way which is easily understandable and 
interpretable by the healthcare professionals. 
4.2.3 Cloud computing 
Sequencing and analysing a person’s whole genome which comprises of 3.2 billion letters 
of the DNA generates 100’s of gigabytes of data. The generation of huge data sets with 
the NGS presents challenges in NHS laboratories by placing a great demand on the 
computational resources and the skills required to handle the data. However, with the rise 
of cloud computing new avenues have opened up for storing and analysing the big 
sequencing data. In cloud computing, customers usually rent the hardware and storage as 
much as they need and pay for the time rented as well as for the storage. Through cloud 
computing, data can be remotely stored and analysis of data can also be performed 
remotely. There is a great need to securely protect the data with strict protocols as privacy 
protection in cloud computing is a major concern (Greenbaum, Du, & Gerstein, 2008) 
(Stein, Knoppers, Campbell, Getz, & Korbel, 2015). If cloud services are to be used by the 
NHS, the data needs to be encrypted before it can be stored in the cloud, and 
consequently this raises issues to do with privacy protection laws and regulations. The 
cost of sequencing has been dropping several times faster than the cost of storing data 
(Stein, 2010). Very soon it will be not feasible to store all the data, and laboratories will 
have to filter huge data sets to identify the informative ones alone and discard the rest. 
Currently in the NHS the genomic data are stored in restricted access computers and are 
108 
 
password protected. A scalable biocomputing infrastructure is essential in order to 
implement the NGS technology in the NHS laboratories. At present, the NHS is harvesting 
the power of technology to digitalise all patient information to provide exceptional care by 
providing clinicians the access to all the patient information through world-class digital 
technology. Through the GDE initiative, all the patient information will be digitally 
encrypted and stored securely in cloud-based systems which can be securely accessed 
by the relevant professionals. Through digitalisation and cloud computing, the NHS will 
create a healthcare system free of paper at the point of care (NHS England, 2017). 
4.2.4 Data governance 
In the context of healthcare data, it is important to acknowledge the words of John Bell 
“One of the most important resources held by the UK health system is the data generated 
by the 65 million people within it” (J. Bell, 2017). Data governance in the NHS refers to the 
handling of patient information in a confidential and secure manner to appropriate ethical 
standards. Data governance provides a consistent framework to staff in the NHS to deal 
with the availability, usability, integrity and security of patient information. Genomic data 
needs to be protected and its privacy and confidentiality needs to be preserved. Artificial 
Intelligence could be an option for the NHS of the future  to safe guard the genomic data 
by various processes such as by encrypting the data, protecting systems using passwords 
and by having an audit of the data access, exchange and transfer. It is also important to 
have local data governance policies along with the protection offered by the supplier. 
Detailed auditable information is essential while dealing with confidential patient 
information on its access and usage. Our study findings reveal that there is no auditable 
information available on the bioinformatic analysis performed on the BaseSpace®. This is 
very significant especially in an NHS setup; it is important and mandatory to have 
auditable information on any analysis performed on the patient samples. The Galaxy 
platform was used to perform bioinformatic analysis on samples which were discordant 
from the reference lab findings. Through our study, we found that for auditable purposes 
platforms such as Galaxy would be very useful in an NHS setup as there is auditable 
information available on the analysis at each step right from uploading the raw .fastq files 
till the results output stage. However, through our study we were also able to identify that 
without any experience in bioinformatics or without the support from bioinformaticians, 
designing a pipeline on Galaxy for bioinformatic analysis can be a daunting task. Hence, it 
is important for the NHS to invest in training our professionals in bioinformatics as NGS 
becomes an integral part of our routine molecular diagnostic services. As evident from 
literature (Desai & Jere, 2012) and from the study findings, I conclude that in the current 
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NHS diagnostic molecular laboratories, bioinformatic data analysis will be one of the 
biggest challenge for implementation of NGS in routine clinical diagnostic services. 
4.2.5 Costing 
It is well known through the literature that post completion of the Human Genome Project, 
the costs of sequencing the human genome have considerably dropped. It took 
approximately 10 years to sequence the first human genome and then 3 years for 
completing the data analysis, with a price tag of approximately 3 billion USD (Illumina, 
2012a). Thus, with recent developments in NGS technology in the post genomic era the 
costs have been considerably brought down which has allowed experiments to be 
performed which were once unimaginable. Currently, through NGS we have developed 
the capability to sequence five human genomes in a single run and produce data within a 
week at a price tag of 5000 USD per genome (Illumina, 2012b). This dramatic price 
decrease, especially with targeted NGS in comparison to whole genome sequencing 
(WGS) and whole exome sequencing (WES), has allowed us to witness genomic 
discoveries being made and published almost on a weekly basis. At present, the 
economic impact of additional incidental findings through WGS and WES is still unknown 
and hence our targeted approach would be the model of choice for the NHS laboratories. 
Our targeted NGS approach in the diagnosis and screening of FH by multiplexing large 
number of samples and simultaneously sequencing them in a single run is a much better 
substitute for WGS and WES since it can be performed at a lower fraction of the cost in 
comparison to those global approaches. In addition, our targeted NGS approach also 
generates less data and has less turnaround times in comparison to the WGS and WES, 
and indeed similar views have been expressed by many others as witnessed from the 
House of Commons report on Genomics and Genome Editing in the NHS (Science and 
Technology Committe. House of Commons., 2018). At present, there are off the shelf 
bespoke panels which can also detect CNV’s, eliminating the need for further traditional 
approaches and WGS. These targeted panels could therefore be the best option for busy 
NHS laboratories. They would be the most cost-effective option, as well as time-saving for 
busy scientists, eliminating the need for further extensive wet lab validation and 
optimisation. A recent study finding (Futema et al., 2012) also supports our view that a 
targeted NGS approach through MiSeq platform can significantly reduce the costs as well 
as reduce the time spent on data analysis. In conclusion, targeted sequencing can be 
more cost-effective in comparison to genome-wide approaches, and furthermore preclude 
the ethical implications and the associated issues surrounding incidental findings. 
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4.2.6 Health Economics 
Health economics is a branch of economics which studies the efficient allocation of 
healthcare resources (Whittington, 2008). It informs decision-makers on which health 
treatments, medications or technologies to support, and from which areas to disinvest, in 
order to maximise population health (Whittington, 2008). NGS technologies have 
revolutionised our scientific communities and has allowed us to understand and practice 
medicine at a level which was once unthinkable. However, despite its success and major 
impact, the translation of NGS from research into routine diagnosis has been limited due 
to the lack of economic evidence. Despite the lack of economic evidence, optimism still 
exists in relation to the integration of genomic technologies into routine clinical settings so 
as to reduce overall healthcare expenditures (S. G. Nicholls et al., 2013). Recently, 
however, this optimism has been scaling down among the scientific community as we 
have been witnessing a steep rise in the costs of downstream analysis. The cost of 
sequencing per base has been falling, however, conversely the cost of bioinformatics 
analysis, variant identification, clinical interpretation and reporting has been increasing 
(Christensen, Dukhovny, Siebert, & Green, 2015) (Buchanan, Wordsworth, & Schuh, 
2013) (Science and Technology Committe. House of Commons., 2018).  
Economic evaluations of implementing NGS in an NHS laboratory setup should take into 
account of the costs right from the point of sample collection, laboratory testing, data 
analysis, reporting of test results, training, resources and the infrastructure. The economic 
impact of laboratory results in the timely diagnosis, treatment and management of patients 
can be huge. It may be argued that the laboratory testing and the analysis costs can be 
insignificant when compared to the downstream costs associated with medical procedures 
and interventions ordered in response to the laboratory findings (Christensen et al., 2015).  
However, it is evident from the literature that health economic studies strongly argue in 
favour of systematic screening of FH (Brice, Burton, Edwards, Humphries, & Aitman, 
2013). The UK could save almost £380 million by preventing CHD events if the relatives of 
the index cases were identified and treated over a period of 55 years, equating the 
savings to £6.9 million per year (Heart UK, 2012). In addition, the findings of a study on 
FH has shown that structured models of care undertaken in their study have proven to be 
more cost-effective than estimated by the NICE (Pears et al., 2014). It is also evident from 
the literature that detection and treatment of FH is cost-effective (Alonso et al., 2008) 
(Marang-van de Mheen, Ten Asbroek, Bonneux, Bonsel, & Klazinga, 2002) (D Marks et 
al., 2000) when compared with the healthcare interventions at a later stage due to CHD. 
Similarly, a recent study in the UK has also shown cascade testing on relatives suspected 
to have FH was found to be highly cost-effective and the adoption of cascade testing will 
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yield substantial quality of life and survival gains (Kerr et al., 2017). In addition, with 
particular reference to a targeted NGS screening approach, it also well-known from the 
literature that applying this approach for FH is more cost-effective and accurate compared 
to WES (Brautbar et al., 2015) (Futema et al., 2012). 
In this FH-NGS study, the cost of the reagents per sample was approximately £54.82 
which was based on the reagent costs in April 2016. The cost per sample is heavily 
dependent on the instrument usage and without prior expert knowledge in economics it 
was not possible to calculate the equipment usage cost and labour costs. This could have 
probably incurred an additional cost of about £200 approximately in addition to the 
reagent costs.    
Compounding all these issues to perform a health economics evaluation of FH-NGS was 
beyond the scope of this study and requires detailed systematic analysis on its own and 
expert academic knowledge in the field of economics to be able to fully assess the health 
economics of FH-NGS in NHS laboratories. It is also important to note that economic 
evaluations of genomic technologies in particular pose a number of methodological 
challenges to health economists itself (Buchanan et al., 2013). It is also evident from the 
literature that health economists are also unsure if the current existing economic 
evaluation models are sufficient to evaluate these genomic technologies (Buchanan et al., 
2013). However, it is necessary to acknowledge that the health economics evaluation of 
FH-NGS could significantly contribute to an efficient allocation of the available scarce 
resources in NHS laboratories. One of the ways to decrease the cost in the NHS 
laboratories is to streamline the workflow, increase the number of samples being analysed 
as the cost per sample are heavily dependent on the instrument usage, integrating NGS in 
the routine molecular diagnostics in areas beyond FH, and automating the full process 
(Yohe & Thyagarajan, 2017). 
4.2.7 Genetic services reconfiguration 
Genomics England, through their ‘100,000 Genome Project’ is providing a roadmap for 
NHS molecular laboratories in the UK to learn and embrace the NGS technology in their 
routine diagnostics and thereby provide a personalised or precision medicine to the 
patients. It is expected, on completion of the ‘100,000 Genome Project’, NHS England in 
partnership with Genomics England will be involved in embedding genomic medicine into 
routine NHS care pathways (Science and Technology Committe. House of Commons., 
2018). The ‘100,000 Genome Project’ has the potential to catalyse and bring about a 
system change in the NHS diagnostics very soon. This however, brings great challenges 
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as well as opportunities to the NHS molecular laboratories and hence it is very important 
to engage all the key stake holders including the public.  
The revolution in sequencing technology through NGS has led to the production of 
sequencing machines in size from the giant ones to the bench top ones. These analysers 
can generate massive amount of data and swamp the current computing infrastructures in 
the NHS laboratories. They also bring along complex challenges as regards data analysis 
and storage. Hence, Health Education England started funding to provide more training to 
healthcare professionals in the NHS to enhance their understanding and knowledge in this 
emerging field by developing programmes such as MSc in Genomic Medicine and through 
some online courses in genomics and bioinformatics. These courses are specially 
designed for healthcare professionals working in the NHS to improve their skills as well as 
to integrate genomic technologies into the patient care in the NHS. However, it is 
important to acknowledge that expert knowledge in bioinformatics will be required to deal 
with complex bioinformatics challenges if NGS is to be implemented in routine NHS 
laboratories. Furthermore, infrastructure, resources and computational requirements pose 
additional challenges to NHS laboratories. Hence, there is a planned reconfiguration of 
regional services with the required infrastructure, computing facilities and professionals 
with great expertise and experience in genomics to provide comprehensive and 
specialised genetic services (Bruce Keogh, 2015). Currently, plans are underway to have 
a network of genomic hub laboratories and local genomic laboratories to deliver a specific 
list of genomic tests and a central data repository connected to a wider NHS digital 
infrastructure (Science and Technology Committe. House of Commons., 2018). This 
opportunity could be used to embrace NGS in NHS routine diagnostic services for 
screening and diagnosis of simple and single gene disorders such as FH. Our FH-NGS 
study serves as an example of how an existing NHS molecular laboratory can start 
piloting this new technology in their diagnostic services. It also can accelerate the 
integration and uptake of NGS into routine NHS diagnostics. It can be argued here that 
implementing NGS locally has its own values and benefits; the clinicians can tailor 
effective management strategies in a timely manner, sample turnaround times can be 
significantly reduced, costings involved in sample transport to the labs can be saved, 
scientists can become specialised and develop expertise in the relevant areas. Regional 
centres with big infrastructure, resource, computational facilities and experts in the field 
can aid in providing expert knowledge and skills to the developing NHS labs, and should 
be able to deal with complex cases which the local labs could not deal with and offer 
training to the small NHS labs. However, in the current NHS landscape it is not clear how 
the genetic reconfiguration would happen and what impact it would have on the molecular 
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diagnostic labs in the NHS, and whether FH testing should be adopted locally or be 
centralised. Evaluating the health economics through cost-benefit analysis and measuring 
the outcomes in terms of quality-adjusted life-years (QALYs) of local and regional services 
can break the political barriers and also can be an important driving factor in the 
reconfiguration of genetic services in the UK. One option for the NHS could be developing 
partnerships with universities and private companies so that they could bring in more 
investments into the NHS to meet the infrastructure demands, computational 
requirements and the financial challenges. However, these should be carefully planned as 
they could bring about challenges in legal liability, data ownership and privacy issues. In 
the current political climate and in the current NHS landscape, it is a policy of ‘wait and 
see’ what the reconfiguration brings and means to the existing NHS molecular labs. 
4.2.8 FH services 
It is evident from the literature that various approaches and screening strategies are being 
followed across the world to provide an effective FH diagnostic service. Critiques have 
argued and discussed the advantage and disadvantage of these approaches in their 
respective settings. For example, in Slovenia, universal screening of children for FH is 
being implemented from the age of 5 (Kusters et al., 2012) where as in other parts of the 
world this approach has remained a subject of controversy (Newman & Garber, 2000). In 
the UK, NICE guidelines advices that children with FH should be identified before the age 
of 10, so that the treatment could be started early (A S Wierzbicki et al., 2008). In the US, 
universal screening of children aged 9-11 is recommended (National Heart, Lung, 2011) 
whereas the same approach is not being recommended by the Royal Australian College 
of Practitioners (Practitioners, 2009). Index cases are usually identified by opportunistic or 
targeted systematic screening (Børge G. Nordestgaard et al., 2013). An Australian study 
team has reviewed various approaches for screening FH, i.e. such as opportunistic 
screening for family history, opportunistic screening of lipids, systematic screening of 
general practice electronic records and universal screening for a general practice setting 
(Kirke, Watts, & Emery, 2012). However, such approaches in the UK are debatable and 
also may not be cost-effective. The UK literature evidences cascade screening as the 
most cost-effective screening strategy (Dalya Marks et al., 2002). The first successful 
national genetic cascade screening was from the Netherlands in 1994 (Umans-
Eckenhausen, Defesche, Sijbrands, Scheerder, & Kastelein, 2001) (Wonderling et al., 
2004), followed by Norway in 2003 (Leren et al., 2004) (Leren, Finborud, Manshaus, Ose, 
& Berge, 2008). This successful cascade screening strategy is also being followed in 
other countries such as Spain (Pocovi, Civeira, Alonso, & Mata, 2004) (Fernando Civeira 
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et al., 2008), New Zealand (Muir, George, Laurie, Reid, & Whitehead, 2010) and Wales 
(Taylor et al., 2010). 
At UHS, cascade screening has been found to be an effective tool in the screening and 
diagnosis of FH. On identification of an index case at the lipid clinic in the UHS, their first 
degree “at risk” relatives are approached as a part of the cascade screening process with 
their consent. These patients are seen and managed by a specialist team of clinical 
consultant, specialist FH nurses and FH genetic counsellor. Blood samples from the first 
degree relatives of the FH index case are sent to a reference lab for FH genetic 
screening. If they are found to have FH, they are managed appropriately with appropriate 
management strategies. GPs also refer suspected cases to the UHS lipid clinic and if they 
found to have FH they are then managed either by the primary care specialist or by the 
referring GP practices. Regardless of the FH genetic testing outcome, the genetic 
counsellor plays a very important role in the FH management pathway and aids the 
patient and their families to make informed choices (Sturm, 2014). It is also evident from 
the literature that genetic counselling helps patients to conceive and acclimate themselves 
to the medical and physiological implications of genetic contributions to the disease 
(National Society of Genetic Counselors’ Definition Task Force et al., 2006). Studies have 
also shown that involvement of a genetic counsellor right from the process of requesting 
tests and reviewing the ordered genetic tests could lead to huge savings and decrease 
wastage (Miller et al., 2014).  
In the current rapid pace of genomics, this study strongly suggests that the 
implementation of NGS in the screening and diagnosis of FH at the UHS will make a 
substantial impact on cascade screening as it will aid in early identification of “at risk” 
relatives of the probands. This will also aid in their early management, thereby preventing 
considerable mortality and morbidity due to CHD at later stages of life. NGS technology 
will allow us to perform the genetic screening of FH as a standard in-house clinical 
practice in the lipid clinics as well as by GP services across the UK. 
4.3 Recommendations 
Current Sanger screening methodologies are sensitive and specific; however they are 
impractical for routine screening purposes as well as for screening large populations due 
to the time and cost involved. NGS is considered to be a paradigm shift in technology 
since a large number of samples can be analysed in one run with minimal human 
interference through automated protocols. Hence it becomes very significant for the future 
NHS laboratories to embrace this technology to meet the demands of the increasing 
diagnostic needs in the most cost-effective way to aid in timely diagnosis and 
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management. Since the technology is becoming more economical, it is also necessary for 
the NHS of the future to implement NGS towards the approach of personalised medicine. 
However, it is important to acknowledge that concurrent training of healthcare 
professionals is crucial in order to successfully implement NGS in routine NHS diagnostics 
as it requires new skills. As evident from the House of Commons report, there are 
widespread concerns that the current NHS staff have insufficient training and there is a 
lack of suitably qualified staff in the NHS to meet the demands of genomic medicine 
integration into the routine diagnostic services of the NHS (Science and Technology 
Committe. House of Commons., 2018). Hence, it is important to develop, train and 
integrate the existing workforce which includes diagnostic staff in the laboratories and 
imaging, computer scientists, statisticians, data scientist and bioinformaticians for 
successful implementation of NGS into our routine NHS diagnostics. The lab 
professionals need to be trained to provide the results in a way which is understandable 
and interpretable by the clinicians, who themselves also need to be trained to interpret the 
results provided by the laboratories. Hence, healthcare professionals in the NHS should 
be trained in bioinformatics which will aid them in analysing and understanding the data in 
a more effective way so that diagnosis and management can be tailored appropriately to 
the patients. Another important recommendation would be the use of wet lab validated 
panels in NGS with considerable optimisation and familiarisation phases (Jennings et al., 
2017) before it is in use for routine diagnostics. This will eliminate the need for the labs to 
perform extensive in-house optimisation and validation and save huge costs and time 
involved in these processes. 
4.4 Limitations 
One of the limitations of this study was that the variant findings could not be compared 
with the patient family history and cholesterol levels, since the samples were fully 
anonymised in this study. This comparison would have enabled me to understand the 
correlation of specific mutations with the blood cholesterol levels and the occurrence of 
CHD. Nonetheless, our main goal in this pilot study was to set up and standardise the 
NGS methodology for the genetic screening of FH and to study the implementation issues 
both at the technical and organisational levels.  
In our study, we were able to achieve a sensitivity rate of 92.54% and a specificity of 
100%. The reason for 92.54% sensitivity was due to the coverage issues with the 
amplicons. This was mainly due to the usage of panels which were in silico validated and 
not wet lab validated by the provider, which is another limitation of our study. However, 
with gap filling Sanger sequencing we were able to achieve 100% sensitivity. This 
limitation could be overcome by using wet lab validated off the shelf bespoke panels 
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which were not available in the market at the time of our study. Nevertheless, our NGS 
approach shows increased rate of sensitivity and specificity in comparison to the current 
traditional sequencing methodologies in use as seen in the literature (Heath et al., 2001) 
(Palacios et al., 2012) (Finnie et al., 2012) (C A Graham et al., 2005). The variant 
detection rates in our FH-NGS study were very similar and comparable to studies 
described in the literature (Futema et al., 2012) (Vandrovcova et al., 2013) (Radovica-
Spalvina et al., 2015). 
4.5 Conclusion 
NGS allowed the identification of FH variants in patients which were not previously 
reported by the reference lab. Moreover, our NGS approach was also able to identify 
numerous variants of unknown significance in LDLR, APOB, PCSK9 and LDLRAP1 
genes. We were also able to identify some of the common variants in LDLR, APOB and 
PCSK9 genes similar to the variants reported in the Latvian population study (Radovica-
Spalvina et al., 2015).  
In contrast with the traditional Sanger capillary sequencing, NGS has allowed us to 
analyse multiple samples in a single run by multiplexing samples. It has the potential to be 
fully automated and errors arising due to human intervention can be minimised. Our NGS 
approach has also found that it can significantly reduce the turnaround times of the 
samples and aid the clinician in diagnosis and tailor appropriate management strategies 
effectively in a timely manner.  
This study has demonstrated the practical utility of NGS to be used by the NHS of the 
future as a diagnostic platform for genetic disorders such as FH. NGS represents a 
paradigm shift from the conventional Sanger sequencing in its ever-increasing breadth of 
coverage, resolution and reliability, coupled with ever-reducing costs. Therefore, 
incorporation of NGS into routine molecular diagnostics will create a major impact on the 
way we diagnose and tailor the management of hereditary disorders such as FH. It will 
also aid in the integration of personalised medicine approach and practice into our routine 
clinical practice in the NHS. 
Based on my personal experience and our study’s findings, I conclude that, with well 
validated panels, appropriate resources together with the bioinformatics support, NGS can 
be effectively translated from the research domain into routine NHS diagnostics. Also, the 
experience gained from this study will be used to implement the applications of NGS in 
other areas beyond FH in the UHS Molecular Pathology laboratory. 
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5. Reflection 
 
5.1 The Professional Doctorate programme 
Soon after completing my Masters degree in Biomedical Science at the University of 
Portsmouth in 2011, I enrolled onto the Professional Doctorate (Prof Doc) in Biomedical 
Science (DBMS) programme at the University of Portsmouth (UoP) in September 2012. 
The programme is composed of two phases: 
Taught phase This phase of the course consist of taught units on ‘Professional Review 
and Development’, ‘Advanced Research Techniques’, ‘Publication and Dissemination’ and 
‘Project Proposal’, which were taught by lecturers at UoP who were experts with up-to-
date knowledge in their respective fields. These units have allowed me to gain an in-depth 
understanding of my strengths and weaknesses, to learn how to formulate research 
questions using different frame-works, develop research proposals. In addition, I have 
also learnt how to critically analyse and appraise qualitative and quantitative research 
articles systematically using the critical appraisal tools. The greatest advantage of this 
taught phase was that the units were taught by lecturers with considerable experience in 
their fields which were then followed by interactive workshops and group discussions to 
facilitate the learning. These interactive discussions and workshops gave student an 
opportunity to apply what was being taught in the lectures. On completion of each unit in 
the taught phase, we were expected to submit an assignment and do a PowerPoint 
presentation in order to progress. These units have greatly enhanced my knowledge and 
understanding on qualitative and quantitative research, as well as enhancing my 
confidence in public speaking and scientific discussions.  
Research phase This phase involved the completion of a workplace research project on 
the application of next generation sequencing (NGS) to aid in effective diagnosis of 
familial hypercholesterolaemia (FH). This research work required an in-depth 
understanding and knowledge of NGS technology and how this new technology can be 
translated effectively into routine diagnostics. To achieve this, I had to learn and 
understand the current practice methods, gather information around my research subject 
to effectively understand the science, enrol myself onto courses to learn and be 
familiarised with the appropriate new technology, and attend lectures and workshops. I 
had to reflect on every situation to effectively assess my own progress and monitor my 
development needs in order to progress and successfully complete this research project. I 
am sure these techniques and methodologies will enhance my future learning and 
research. I feel that this doctorate programme has provided me the required knowledge to 
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bring about changes in diagnostic practices and believe that it has enhanced my 
confidence in public speaking and scientific debates. 
5.2 Researching while working as a full time Biomedical Scientist 
The DBMS programme has been a challenging programme which required discipline and 
dedication. For me it was a very fine line I had to trend in order to effectively balance full-
time work and university life with my family life. I faced a few financial burdens, since I 
was self-funding my DBMS, and to rub salt in the wound, I had no study leave approved 
for this programme at my workplace and hence had to use my annual leave to attend 
university lectures, workshops, and meetings. However, my family was very 
understanding and supported me during this period of financial hardship. Moreover, my 
workplace and university supervisors were very supportive and motivating, which allowed 
me to successfully complete my research. My workplace and university supervisors are 
very busy professionals, each having their own priorities and timelines, but nevertheless 
still made the effort to support me and guide me in my research work. Their expertise, 
knowledge sharing and constructive feedback has allowed me to work more effectively on 
my research project. 
5.3 Bringing about a change in professional practice 
Bringing about change to a procedure or practice in the workplace is never expected to be 
a smooth or flawless process. This research project has helped me to understand how 
NGS can be effectively used to diagnose FH. Through this pilot study, we have gained an 
understanding of how this new technology can be effectively translated from the research 
domain into routine diagnostics. It has also allowed me to understand the implementation 
challenges and how they could be effectively addressed in order to successfully 
implement NGS into our routine molecular diagnostics (e.g. at UHS ) in the near future. It 
is evident from this study and from the literature that NGS will likely aid in effective 
screening and diagnosis of patients with FH. This would allow the clinicians in tailoring 
effective management strategies in a timely manner. The rapid pace of developments in 
NGS technologies has created more opportunities and has opened doors for the NHS 
diagnostic laboratories to embrace this new technology. Furthermore, the potential 
applications of this technology could be expanded to other branches of diagnostics 
beyond FH. Hence, to keep pace, it is important to address that the NHS needs to 
embrace NGS into their routine diagnostics at the earliest feasible opportunity. This study 
will lay a foundation for the implementation of NGS for FH in routine molecular diagnostics 
at the UHS. Implementing NGS at UHS will surely bring in economic benefits to the NHS 
as well as to society as a whole. 
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5.4 Dissemination of information 
During the research phase of this study, the author has presented the provisional findings 
at a local level in the Molecular Pathology Laboratory at UHS which was attended by 
biomedical scientists, clinical scientists, trainees and consultants. At national/International 
level, the output from the study was disseminated through a poster presentation in the 
form of an impact case study poster in the 6th International Conference on Professional 
Doctorates in London 2018. The abstract of this study and the link to the extended 
abstract was published in the conference brochure. The output of the study was 
disseminated through a poster presentation at Research and Innovation Conference at 
the University of Portsmouth on September 2018. 
5.5 Professional development 
The Professional Doctorate in Biomedical Science programme at UoP has created a 
positive impact on my academic career. Through this programme, I feel that I have 
enhanced and developed my academic skills through lectures, assignments, 
presentations, university workshops, as well as by attending and enrolling onto courses 
required for the successful completion of my research project. Whilst on this programme, I 
have had various colleagues at work discussing about their research projects and seeking 
advice on the ethical approval process for their research projects. The knowledge and the 
skills gained through this programme have allowed me to give them a helping hand by 
providing guidance and advice on research projects and ethical approval process. I am 
confident and sure that on completion of my doctorate programme, my horizons will be 
expanded and my opportunities for career development will also be enhanced. 
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Appendix 5  
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